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Resonance-energy-transfer-based fluorescence imaging and free energy perturbation calculation  
Fang Xu 
This thesis focuses on an important aspect of protein functionality – protein-protein 
interactions (PPI). Three physical chemistry techniques for or derived from protein-protein 
interaction investigation are discussed. First, in Chapter 2, we demonstrate a new fluorescent 
imaging technique that creates high-order nonlinear signals by harnessing the frustrated 
fluorescence resonance energy transfer (FRET) – energy transfer between certain proteins close in 
proximity which is commonly used in PPI studies. In Chapter 3, we combine fluorescence 
resonance energy transfer (FRET) and bioluminescence resonance energy transfer (BRET), two 
most commonly used approaches to monitor protein-protein interactions in vivo, to create a novel 
hybrid strategy, bioluminescence assisted switching and fluorescence imaging (BASFI), which 
integrates the advantages of FRET and BRET. We demonstrate BASFI with Dronpa-RLuc8 fusion 
constructs and drug-inducible intermolecular FKBP-FRB protein-protein interactions in live cells 
with high sensitivity, resolution, and specificity. Finally, in Chapter 4, we propose a systematic 
free energy perturbation (FEP) protocol to computationally calculate the binding affinities between 
proteins. We demonstrate our protocol with the gp120 envelope glycoprotein of HIV-1 and three 
broadly neutralizing antibodies (bNAbs) of the VRC01 class and analyze antibody residues’ 
contributions to the binding which further provides insights for antibody design.  
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Protein-protein interactions (PPIs) are biochemical contacts occurring between two or 
more proteins steered by electrostatic forces. These interactions control nearly every aspect of 
normal cellular function. For example, they control extracellular signals propagation inside cells, 
regulate enzymes interactions for cell metabolism and coordinate muscle contractions. It is 
desirable to develop new tools to understand the formations and functions of the interactions on 
both molecular and clinical levels.  
The leading approach to analyze the dynamics of PPIs in vivo is fluorescence (or Förster) 
resonance energy transfer (FRET). FRET is an energy transfer process occurring between two 
chromophores close in proximity (<10 nm): a donor chromophore excited by laser to its electronic 
excited state transfers energy to a ground-state acceptor through non-radiative dipole-dipole 
coupling. The energy transfer efficiency is inversely proportional to the sixth power of donor-
acceptor distance. Thus, FRET is extremely sensitive to the distance and well-suited to measure 
protein-protein interactions.  
Several FRET-based techniques have been developed to monitor and quantify protein-
protein interaction. One approach is spectral radiometric imaging technique. With this approach, 
the fluorescence intensity of both the FRET acceptor and donor is collected and the intensity ratio 
is calculated. As FRET occurs, the donor signal intensity decreases and the acceptor signal 
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intensity increases, and the ratio is a good quantitative indicator for protein-protein interaction. 
Acceptor fluorescence depolarization is another popular method. It can achieve similar acquisition 
speeds as spectral radiometric readouts and provide high sensitivity for FRET detection. A more 
recent method is called fluorescence lifetime imaging (FLIM). It is a more robust approach to read 
out FRET since only donor fluorophores need to be measured but the signal intensity is lower 
compared with the other two methods.  
Similar to FRET, bioluminescence resonance energy transfer (BRET) methods also have 
been gaining popularity in protein-protein interaction measurements. The energy transfer 
mechanism in BRET is almost the same as FRET. The only difference is that the donor 
chromophore in BRET is a luciferase instead of a fluorescent protein, which is excited to its excited 
state through oxidation reaction between the luciferase and an added substrate coelenterazine. No 
laser illumination upon the donor is required in this method.   
A major advantage of FRET is to visualize protein activities in a single living cell at 
subcellular level. This is difficult for BRET methodology because of low signal intensity generated 
by luciferase light emission. However, because the donor chromophore needs to be excited upon 
laser illumination, FRET measurement approaches suffer from bleedthrough problem due to the 
overlapping absorption and emission spectra of the donors and acceptors. Thus, additional 
measurements to quantify readouts of FRET efficiency is needed. Since BRET donors are excited 
by substrate coelenterazine, its quantification process is more straightforward.  
Chapter 2 and Chapter 3 will focus on new imaging methodology development based on 
FRET and BRET. In Chapter 2, the mechanism of FRET is utilized to create high-order non-linear 
3 
 
effect with regular two-photon fluorescence imaging which enables deep-tissue imaging with high 
contrast and high spatial resolution, as originally published in Optics Express. In this technique, a 
three-order and a four-order non-linear imaging effect is generated by frustrating the Förster 
resonance energy transfer between the donor and the acceptor by simultaneously illuminating the 
donor and the acceptor.  
Next, Chapter 3 describes a novel hybrid protein-protein interaction imaging strategy – 
bioluminescence assisted switching and fluorescence imaging (BASFI). In this approach, a 
bioluminescent Renilla luciferase RLuc8 is used as the donor and a photochromic fluorescent 
protein Dronpa as the acceptor. A photochromic fluorescent protein has a dark state, which cannot 
generate fluorescent signal upon laser illumination, and a bright state. The resonance energy 
transfer from the donor to acceptor, can switch Dronpa from its original dark state to a stable bright 
state. BASFI combines FRET’s advantage - the high photon flux and BRET’s advantage – minimal 
bleedthrough. The original paper was published in The Journal of Physical Chemistry Letters. 
In addition to experimentally observing and quantifying PPIs inside living cells, another 
challenging objective is to identify residues that significantly contribute to certain protein 
interactions. A deep understanding is very useful for drug design since the origins of many diseases 
often lie in PPIs. Particularly, protein-based drugs involved in large PPIs interfaces, such as 
monoclonal antibodies, have been increasingly desired. Considering that the experimental methods 
are expensive and time-consuming, computational modeling has become the trend in protein-based 
drug design.  
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A considerable number of computational approaches have been developed for protein-
ligand binding affinity calculation in the past few years, which have achieved good accuracy (< 
1kcal/mol) with the development in simulation algorithms, molecular mechanics force fields, and 
computational hardware.  Given the complexity of the antibody-antigen interference, the methods 
for protein-ligand calculation cannot be directly applied in antibody-antigen cases. In Chapter 4, 
we report a new systematic free energy perturbation (FEP) protocol which has significantly 
increase the accuracy of relative protein binding affinity calculation. The concept is demonstrated 
with the calculation of relative binding affinities of the gp120 envelope glycoprotein of HIV-1 and 
three broadly neutralizing antibodies (bNAbs) of the VRC01 class. The original research paper 









Frustrated FRET for high-contrast high-resolution two-photon 
imaging 
Two-photon fluorescence microscopy has become increasingly popular in biomedical 
research as it allows high-resolution imaging of thick biological specimen with superior contrast 
and penetration than confocal microscopy. However, two-photon microscopy still faces two 
fundamental limitations: 1) image-contrast deterioration with imaging depth due to out-of-focus 
background and 2) diffraction-limited spatial resolution. In this chapter, we propose to create and 
detect high-order (more than quadratic) nonlinear signals by harnessing the frustrated fluorescence 
resonance energy transfer (FRET) effect within a specially designed donor-acceptor probe pair. 
Two distinct techniques are described. In the first method, donor fluorescence generated by a two-
photon laser at the focus is preferentially switched on and off by a modulated and focused one-
photon laser beam that is able to block FRET via direct acceptor excitation. The resulting image, 
constructed from the enhanced donor fluorescence signal, turns out to be an overall three-photon 
process. In the second method, a two-photon laser at a proper wavelength is capable of 
simultaneously exciting both the donor and the acceptor. By sinusoidally modulating the two-
photon excitation laser at a fundamental frequency ω, an overall four-photon signal can be isolated 
by demodulating the donor fluorescence at the third harmonic frequency 3ω. We show that both 
the image contrast and the spatial resolution of the standard two-photon fluorescence microscopy 
can be substantially improved by virtue of the high-order nonlinearity. This frustrated FRET 
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approach represents a strategy that is based on extracting the inherent nonlinear photophysical 
response of the specially designed imaging probes. 
2-1. Introduction  
Modern optical microscopy has greatly opened up exciting opportunities for imaging 
biological samples. For high-resolution (sub-cellular) imaging in live tissues and organisms, two-
photon (2P) fluorescence microscopy is the most appealing tool [1-3]. It uses localized nonlinear 
excitation to generate fluorescence signal within the focus volume where the probability of 
absorbing two simultaneous incident photons in a single event is the highest [4]. In comparison to 
one-photon confocal microscopy, such spatially confined excitation (i.e., optical sectioning) of 2P 
microscopy enables higher image contrast and hence deeper penetration for scattering samples. 
However, 2P microscopy will finally lose its image contrast when the optical sectioning 
ability eventually breaks down when focusing deep into scattering samples. Due to the scattering 
loss, the laser power is attenuated exponentially along the light path. Increasing the total excitation 
laser power with imaging depth helps to maintain the same excitation intensity at the focal plane, 
but inevitably also reaises the probability of exciting the out-of-focus fluorophores (especially 
those located near the sample surface). As a result, the out-of-focus background will grow and 
eventually overwhelm the in-focal signal when approaching the fundamental imaging-depth limit 
[5-8]. Obviously, such loss of image contrast cannot be overcome with a higher excitation laser 
power which will enhance the signal and background equally. A number of strategies have been 
devised to address this challenge, including using longer excitation wavelength [9], adaptive optics 
7 
 
[10, 11], differential aberration [12], structured illumination [13], optical phase conjugation [14], 
spatial and temporal focusing [15] and focal modulation [16].  
In addition to the loss of image contrast, 2P microscopy also suffers from relatively coarse 
diffraction-limited spatial resolution [17, 18]. Due to the long excitation wavelength and moderate 
numerical aperture of the objective, the lateral resolution of 2P microscopy is only about 400 nm 
which obscures many interesting features such as dendritic spines. Although several super-
resolution techniques (PALM [19], STORM [20], SIM [21], SOFI [22] and STED [23]) have been 
developed to break the diffraction limit, only STED [17, 23, 24] is compatible with 2P imaging 
because STED is equipped with single-element detectors rather than CCD cameras. Unfortunately, 
it is technically challenging for two-photon STED to spatially shape a doughnut beam with clean 
intensity null deep inside highly scattering samples.  
              
Fig. 2-1. Principle of frustrated FRET. (a) When only the donor is excited, the fluorescence 
resonance energy is transferred from the donor to the acceptor, quenching the donor fluorescence.  
(b) When the donor and the acceptor are excited at the same time, FRET is inhibited, recovering the 





Herein we propose a new concept of harnessing higher-order (more than quadratic) 
nonlinear fluorescence to improve both the spatial resolution and image contrast of 2P microscopy. 
Instead of involving more virtual states, the super nonlinearity is created by frustrated FRET, i.e., 
blocking energy transfer from the donor to the acceptor in a FRET pair. In brief, if the donor alone 
is excited, FRET will occur between the excited donor and the ground state acceptor, which 
quenches the donor fluorescence. In contrast, if the donor and the acceptor are both excited, energy 
transfer will be largely blocked (due to the mismatch of spectral overlap) and thus the donor 
fluorescence will be dequenched and enhanced [Fig. 2-1][25]. Therefore, frustrated FRET is 
inherently a nonlinear process requiring excitation of both donor and acceptor. The concept of 
frustrated FRET was originally proposed to enhance the resolution of confocal microscopy [26, 
27], and was recently applied in selective synchronously amplified fluorescence image recovery 
from a high background [28]. Here we exploit it for enhancing image contrast and the spatial 
resolution of 2P microscopy in scattering samples.  
In this report, we propose two distinct but related experimental schemes to generate and 
detect such super-nonlinearity associated with frustrated FRET. The first technique utilizes a 
modulated one-photon (1P) laser beam to directly excite the acceptor, preferentially switching 
on/off the FRET process. The enhanced donor fluorescence is proved to be an overall three-photon 
process. The second technique employs only one 2P laser that could excite both the donor and 
acceptor. The 2P laser is modulated at a fundamental frequency ω and an overall four-photon donor 
fluorescence signal is deciphered at the third harmonic frequency 3ω through demodulation [29]. 
We present the expected performance of both new 2P imaging techniques with analytical theory 
and numerical simulations.  
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2-2. Results and discussion 
2-2.1 Frustrated FRET implemented with two excitation beams     
                           
Fig. 2-2. Frustrated FRET with two excitation beams. (a) The proposed experimental setup in which 
the 2P laser and the 1P laser are collinearly combined with each other and focused onto the same 
focal spot. The 1P laser beam is being modulated, and the demodulated donor fluorescence is used 
as the new signal contrast. (b) A simplified Joblonski diagram illustrating that the energy is blocked 
by simultaneous excitation of both the donor and the acceptor. (c) Synchronized donor/acceptor 
excitation pulse trains. The 1P laser pulses are temporally followed by the 2P laser pulses with a 
time gap shorter than 1ns, which avoids the potential stimulated emission of the donor but still 
blocks FRET efficiently. The final image is reconstructed from the enhanced fluorescence signal 
which is demodulated from the lock-in amplifier.  
In the first approach, as shown in Fig. 2-2(a), a two-photon (2P) laser for donor excitation 







and 1P excitation beams are pulsed lasers (synchronized at the same frequency ~ 80MHz) with 
pulse widths of ~100fs and ~1ns, respectively. As the fluorescence lifetime (~ 3ns) is much shorter 
than the pulse spacing (~ 13ns), the donor and the acceptor are treated on their ground states right 
before each pulses. Note that to avoid the potential donor stimulated emission caused by the 1P 
excitation beam, the 1P pulse train is temporally ahead of the 2P train for each pulse by sub-
nanoseconds [Fig. 2-2(c)]. The 1P laser is intensity modulated at a high frequency (~ 5MHz). 
When the 1P laser is blocked, an efficient FRET occurs from the 2P-excited donor to the ground 
state acceptor, resulting in a low donor fluorescence signal. In contrast, when 1P laser is unblocked, 
the acceptor will be brought to the excited state right before the action of 2P pulses, which inhibits 
FRET process and enhances the donor fluorescence. The final image is thus reconstructed from 
the enhanced donor fluorescence signal detected by a lock-in amplifier at the modulation 
frequency. In principle, all regular FRET pairs can work for this technique. In practice, we prefer 
donors to have high 2P absorption cross-section and high quantum yield. Besides a fluorophore, 
the acceptor could also be a non-fluorescent quencher. Fluorophores or quenchers with red-shifted 
excitation spectra are preferred as the FRET acceptors, in which case the wavelength of the 1P 
acceptor excitation laser (λ1P) will be close to that of the 2P donor excitation laser (λ2P), ensuring 
similar attenuation effects.  
Quantitatively, under illumination by a train of 2P laser pulses, the excitation rate constant 
of the donor within the short laser pulses is related to  PI2  through 




















                                       (2-1) 
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Similarly, the excitation rate constant of the acceptor within the 1P laser pulse is related to 
PI1  through 



















                                          (2-2) 
where Pd 2,  is the two-photon absorption cross section (GM) of the donor at wavelength
P2 , Pa 1,  is the one-photon absorption cross section (cm2) of the acceptor at wavelength P1 , repf  
is the repetition rate (~80 MHz), P2  is 2P pulse width (~100 fs) and P1  is 1P pulse width (~1 ns). 
The probability of the donor or the acceptor being excited to the excited state after each 
laser pulse is determined by the first-order kinetics )exp(1 pulseexckP  . Note that there will be 
negligible excited-state molecules decaying back to the ground state within the short pulse 
duration. Under the non-saturating condition, the probability simplifies to pulseexckP  . Because the 
excitation of the donor and the acceptor are independent processes, after each pulse, the 
probabilities of the donor and the acceptor being excited to the excited states are 




















                                    (2-3)  
and 



















                                      (2-4) 
12 
 
When the 1P acceptor excitation laser is blocked (off) during the modulation procedure, 
energy will be transferred between the excited donor and ground state acceptor, quenching the 
donor fluorescence. The donor fluorescent emission rate in the absence of 1P excitation beam is 




















                    (2-5) 
where N is the number of fluorophores, ε is the collection efficiency, dflk .  is the 
fluorescence emission rate of the donor, τ is the intrinsic donor fluorescence lifetime, and FRETk  is 
the energy transfer rate. We have assumed the original donor fluorescence quantum yield as unity. 
                          
Fig. 2-3. Several possible fates of the PD (t) population are considered when the 1P acceptor 
excitation beam is on. The capital letters denote the excited states of the donor (D) and acceptor (A), 
and the small letters denote the ground states of the donor (d) and the acceptor (a).  
 We then consider the case when the 1P acceptor excitation beam is on. As schematized in 
Fig. 2-3, the donor fluorescence quantum yield is determined with two possible scenarios after 
each pulse: the acceptor remains in the ground state, which has a probability of AP1 , and the 




the donor fluorescence quantum yield for such a D-a pair is the same as that in Eq. (5), i.e., 
    FRETk /1//1 .
 
For the second scenario of the excited D-A pair, if assuming comparable 
fluorescence lifetimes for the donor and the acceptor, there exist two sub-scenarios with certain 
chances (we assume the chance to be 50:50). If the acceptor is relaxed to the ground state earlier 
than the donor, the donor fluorescence quantum yield is given by Eq. (2-5) as well. On the other 
hand, if the acceptor is relaxed to the ground state later than the donor, the donor fluorescence 
quantum yield is then 1. Therefore, we can calculate the weighted donor fluorescence quantum 
yield for DP  population as: 
















































                (2-6) 
where   FRETFRET kk /1/  is the energy transfer efficiency Et. The detected donor 
fluorescence emission rate 'flS  in the presence of 1P beam thus becomes: 











                   (2-7) 
Subtracting Eq. (5) from Eq. (2-7) which is equivalent to the electronic demodulation of 
the lock-in amplifier at the modulation frequency [Fig. 2-2(c)], we finally arrive at the enhanced 
donor fluorescent signal: 





.2 avePavePADtrepenhanced IIPPEfNS                            (2-8) 
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where      hcfhcfEfN PrepPPaPPrepPPdPtrep 111,12222,2 //2/1   . The original two-
photon process has now been turned into an overall three-photon effect after harnessing the 
frustrated FRET effect. It is worth noting that the FRET efficiency (Et) does not affect the super-
nonlinearity generated by frustrated FRET. On the other hand, the detected fluorescence signal 
depends on Et, thus the FRET pairs with high energy transfer efficiencies are desired to achieve 
high photon flux.  
2-2.2 Frustrated FRET implemented with one excitation beam 
                   
Fig. 2-4. Frustrated FRET with one excitation beam (a) The proposed experimental setup in which 
the 2P laser is sinusoidally modulated at the fundamental frequency ω, and the donor fluorescence 
detected and then demodulated at 3ω. (b) A simplified Joblonski diagram illustrating that the energy 
transfer is blocked by simultaneous excitation of both the donor and the acceptor with a two-photon 
laser. 
Now we utilize only one 2P laser beam at a proper wavelength that can excite both the 
donor and the acceptor. It should be easy to design such FRET pairs, as two-photon absorption 




and acceptor candidates, because of the high 2P excitation efficiency at 820~840 nm, bright donor 
fluorescence and small emission overlap [30]. By sinusoidally modulating the excitation 2P laser 
at a fundamental frequency (ω) and demodulating the donor fluorescence at the third harmonic 
frequency (3ω), the higher-order nonlinear signal could be isolated. Thus, a relatively simple 
apparatus can realize this harmonic demodulation concept [Fig. 2-4(a)].   
Upon intensity modulation at fundamental frequency ω (~MHz, which is fast enough for 
point scanning but slower than the pulse repetition), the average 2P excitation intensity could be 
sinusoidally modulated as: 
                                       ,)cos(1)( ,2,2 tItI avePaveP                                  (2-9) 
where avePI ,2  
is the time-averaged value of )(,2 tI aveP , and α is the modulation depth (here 
we assume α = 1). During each pulse, the excitation rate constant within the short laser pulses is 
defined as  



















                                 (2-10) 
The modulated probability of the donor or the acceptor being excited to the excited state 
after each laser pulse is pulsePexc tktP )()( 2, . After each pulse, the probability of the donor and the 
acceptor being excited to the excited states are  
                                             ,cos1)( 2ttP DD                                           (2-11) 
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and      
                                            ,cos1)( 2ttP AA                                           (2-12) 
where  2,22,, / hcfI pulserepavePPpulseDADA   , representing the time-averaged excitation 
probability of a single acceptor or donor. 
Then we determine the fluorescence quantum yield for the )(tPD  donor population. As 
described in the previous section [Fig. 2-3], there are two possible scenarios facing this population 
of )(tPD  after each pulse as well. The resulting modulated quantum yield of the donor fluorescence 
is presented as 












                                (2-13) 
Thus the detected fluorescence emission rate )(tS fl  of the donor is 
                                          ).()()( ttPfNtS Drepfl                                       (2-14) 
Incorporating Eqs. (11)-(13) into Eq. (14), we arrive at: 
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As expected, the donor fluorescent signal consists of both a quadratic term and a quartic 
term.  
Harmonic demodulation technique is then employed to separate the quartic term from Eq. 
(15): modulating the 2P laser beam at a fundamental frequency ω and then demodulating the 
detected fluorescence signal at 3ω. Quantitatively, we expand Eq. (15) into its Fourier series: 
                 ,)4cos()3cos()2cos()cos()()( 4320, tStStStSSfNtS repdfl       (2-16)  
where the Fourier coefficients nS  represent the amplitude of the nth harmonic frequency, 
and have forms as:  
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Assuming that   DA , we obtain the dependence of demodulated donor fluorescent 
signal at the frequencies of ω, 2ω, 3ω, and 4ω as functions of β. As shown in Fig. 2-5, the 3ω and 
4ω harmonic signals scale with β2 only, while the ω, 2ω signals contain a mixture of β and β2 
terms. Since β is given by  2,22 / hcfI pulserepavePPpulse  ,  thus purely four-photon signals can be 
detected at the 3ω and 4ω harmonic frequencies. Furthermore, if assuming tE as 80%, a common 
energy transfer efficiency value between FRET pairs, we will get )125.375.0/(/ 03  SS . If a 
moderate excitation probability (β = 0.1) is assumed, the 3ω harmonic fluorescent signal is about 
9.4% of the regular 2P signal. Therefore, a sizable four-photon fluorescent signal can be detected 
at the 3ω demodulated harmonic frequency.                              
                 
Fig. 2-5. Dependence of demodulated donor fluorescence (after normalization) at ω (Sω), 2ω (S2ω), 
3ω (S3ω) and 4ω (S4ω) as a function of β in the one-laser scheme. Note that β itself scales with 










2-2.3 Enhancement of signal-to-background contrast deep inside scattering samples 
Now we numerically estimate how the above two new frustrated FRET techniques could 
enhance the signal-to-background contrast at fundamental imaging-depth limit of the regular two-
photon microscopy, which is defined as [5-8] 





























                         (2-22)  
where Vin is the focal volume, Vout is the total volume of the sample along the beam path 
except Vin, τ is the pixel dwell time during the imaging, C is the local fluorophore concentration, I 
is the 2P laser intensity, r is the distance from the optical axis, and z is the axial distance from the 
sample surface. We assume that the signal and the background share the same fluorescence 
collection efficiency at the large-area non-descanned detector and the fluorophores are uniformly 
stained ( BS CC  ) throughout the volume. The wavelengths are set as 1000 nm for the two-photon 
laser and 700 nm for the one-photon laser, both of which lie within the transparent optical window 
(650 ~ 1300 nm) of biological tissues. To simplify the calculation, we only consider the ballistic 
photons for samples whose anisotropy factors are low or moderate, and set the mean free path 
length as 200 μm, the value for brain tissues of the near IR region [3]. The intensity is shown as 
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where ls is the mean free path (200 μm), ω0 is the beam waist at the focus (0.35µm), zR is 
the Rayleigh range (0.5µm), and zfocal is the depth of the focal plane. Numerical criteria of S/B =1 
determines the 2P imaging-depth limit to be zfocal=1023m (as shown in Fig. 6), which is very 
close to the experimental result of ~ 1 mm on mouse brain tissues [6].   
                           
Fig. 2-6. Numerical estimation of the fundamental imaging-depth limit (where S/B ratio is 1) of the 
standard 2P microscopy. 
We can further calculate the fluorescence photon flux (in the unit of number of photons per 
microsecond) within the focal volume (Vin) and the background volume (Vout) respectively. The 
fluorescence photon flux of the conventional 2P microscopy is given by 



























                        (2-24) 
According to Eqs. (2-8) and (2-20), the fluorescence photon fluxes of the newly proposed 
higher-order nonlinear techniques are derived respectively as: 
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and                                                                              


































































  (2-26) 
Inserting absolute values of the involved parameters (as listed in Table 1), we calculate the 
signal and background fluorescence photon fluxes, as well as S/B ratio of the conventional two-
photon microscopy, two-laser frustrated FRET technique (enhanced) and one-laser frustrated 
FRET technique (3ω) (Table 1). Our numerical analysis indicates that the two newly proposed 
frustrated-FRET techniques can dramatically improve the image-contrast at the fundamental 
imaging depth limit of the standard 2P microscopy. Specifically, the two-laser  strategy, which 
finally creates three-photon effect, increases the signal-to-background ratio from 1 (normal 2P 
microscopy) to 46.2; and the one-laser strategy, which creates four-photon effect, enables an 
improvement of S/B from 1 (normal 2P microscopy) to 294. 
Table 2-1: Comparison of the standard two-photon microscopy, the two-laser 
frustrated FRET and the one-laser frustrated FRET at the fundamental imaging 













Background photon flux [photon 
µs-1] 2.06×10
3 5.24×100 5.61×10-2 
Signal-to-background ratio 1 46.2 294 
*The signal and background fluorescence photon fluxes were calculated with a fluorophore 
concentration of 1.66×10-5M, a collection efficiency of 0.5, and a FRET efficiency of 80%. The 
powers were set as 200mW for the 2P laser and 20mW for the 1P laser. Both the two lasers had a 
repetition rate of 80MHz and the pulse width were 100fs and 1ns of the 2P and 1P lasers respectively. 
The two photon cross section of both the donor and acceptor fluorophores were assumed as 100GM 
and the one photon cross section of the acceptor were assumed as 2×10-16cm2.   
Along with the substantially improved signal-to-background ratio, the super nonlinearity 
created by frustrated FRET is inevitably associated with a lower fluorescence photon signal than 
the standard 2P microscopy (Table 2-1). Hence, the issue of shot noise becomes relevant here. In 
order for the new techniques to deliver equal signal-to-noise levels as that of the traditional 2P 
microscopy, prolonged pixel dwell times are needed. For instance, if a 512 pixel×512 pixel image 
is taken at 200 Hz with a standard 2P microscopy, which means the pixel dwell time is around 10 
µs, 2.06×104 photons in total will be collected from a single pixel within the focal volume. To 
collect a similar number of signal photons, the two-laser technique requires around 85 µs pixel 
dwell time and the one-laser technique requires around 1250 µs pixel dwell time, which correspond 





2-2.4 Improvement of the spatial resolution in 3D 
In addition to enhancing the signal-to-background contrast deep inside the scattering 
samples, the super-nonlinearity created by frustrated FRET could also contribute to the 
enhancement of the spatial resolution. For regular 2P microscopy, the point-spread-function 
(PSF2P) is the square of the illumination PSF of the 2P excitation laser: 
       222 ),,(),,( zyxIPSFzyxPSF PP                                  (2-27) 
In the case of two-laser frustrated FRET, the enhanced donor fluorescence signal depends 
on PP II 122 . Hence, the PSFenhanced is defined as 
),,(),,(),,( 1
2
2 zyxIPSFzyxIPSFzyxPSF PPenhanced                 (2-28) 
Meanwhile, 3ω harmonic donor fluorescent signal is actually a four-photon signal, which 
means PSF3ω is the fourth power of IPSF2P(x,y,z)  
        422 ),,(),,( zyxIPSFzyxPSF PP                                 (2-29) 
ISPF2P(x,y,z) follows a Gaussian-distributed function, and the 1/e widths of lateral and 
axial profiles for 22 ),,( zyxIPSF P  are given by ..2/320.0 ANxy    and 
)..(2/532.0 22 ANnnz   , respectively [31].   
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When using an air-objective with a N.A.=0.7, the diffraction index (n) as 1, 2P laser 
wavelength as 1000 nm and 1P laser wavelength as 700 nm, we could plot the point-spread-
functions of the donor fluorescence of regular 2P fluorescence signal, enhanced donor fluorescence 
signal and the harmonic 3ω signal based on Eqs. (2-27)-(2-29). Fig. 2-7 indicates the apparent 
resolution enhancements by both the frustrated FRET techniques. Compared with the regular 2P 
microscopy, it is apparent that the one-laser technique (four-photon effect) increases the spatial 
resolution by a factor of sqrt(2) in all three dimensions. Meanwhile, the two-laser technique (three-
photon effect) also improves the resolution by ~1.4 times owing to the relatively shorter 
wavelength of the 1P laser than that of the 2P laser. 
                               
Fig. 2-7. Both the two-laser and one-laser frustrated FRET techniques can improve the spatial 
resolution of the regular 2P microscopy in all three dimensions. We assume that the images are 
taken with an air-objective of N.A. = 0.7, refraction index of 1, and the 2P and 1P laser wavelengths 
to be 1000 nm and 700 nm, respectively. The color bar linearly depends on the fluorescence 





In summary, a new concept of super-nonlinear fluorescence microscopy based on the 
frustrated FRET effect is proposed to significantly improve image contrast, as well as to enhance 
the diffraction-limited spatial resolution, of two-photon microscopy deep inside scattering 
samples. In this article, we described two techniques to generate and detect the higher-order 
nonlinear signals. In the first approach, we excite the donor and acceptor respectively with two 
collinearly combined laser beams, and detect the resulting enhanced fluorescence signal. In the 
second approach, we exploit a single 2P laser beam to excite both donor and acceptor and separate 
the four-photon signal through harmonic demodulation. Each of these two techniques has its own 
advantages. The two-laser method allows more efficient and flexible excitation arrangement and 
hence has a wider range of applicable FRET probes; while the one-laser method requires a 
relatively simple experimental apparatus. Moreover, by prolonging the collection dwell time 
accordingly, a signal-to-noise level similar to that of conventional 2P microscopy can be achieved. 
Finally, the current approach can be compared with the recently developed deep-imaging 
methods using photo-activatable fluorophores [32, 33, 34]. Both frustrated FRET techniques and 
mutiphoton activation and imaging of photo-activatable fluorophores represent molecule-based 
(rather than wave-based) strategies of harnessing special imaging probes with inherent nonlinear 
response. Owing to the faster temporal response of energy transfer process over chemical bond 
breaking required in photo-activatable fluorophores, the frustrated FRET techniques should be 





1. R. Yuste, ed., Imaging: A Laboratory Manual (Cold Spring Harbor Laboratory, 
2010). 
2. W. Denk, J. H. Strickler, and W. W. Webb, “Two-photon laser scanning 
fluorescence microscopy,” Science 248, 73-76 (1990). 
3. F. Helmchen and W. Denk, “Deep tissue two-photon microscopy,” Nat. Methods 2, 
932-940 (2005). 
4. B. R. Master and P. T. C. So, Handbook of Biomedical Nonlinear Optical 
Microscopy (Oxford University , 2008). 
5. P. Theer and W. Denk, “On the fundamental imaging-depth limit in two-photon 
microscopy,” J. Opt. Soc. Am. A. 23, 3139-3149 (2006). 
6. P. Theer, M. T. Hasan, and W. Denk, “Two-photon imaging to a depth of 1000 μm 
in living brains by use of a Ti:Al2O3 regenerative amplifier,” Opt. Lett. 28, 1022–1024 (2003). 
7. J. Ying, F. Liu, and R. R. Alfano, “Spatial distribution of two-photon-excited 
fluorescence in scattering media,” Appl. Opt. 38, 224-229 (1999). 
27 
 
8. N. J. Durr, C. T. Weisspfennig, B. A. Holfeld, and A. Ben-Yakar, “Maximum 
imaging depth of two-photon autofluorescence microscopy in epithelial tissues,” J. Biomed. Opt. 
16, 026008 (2011). 
9. D. Kobat, N. G. Horton, and C. Xu, “In vivo two-photon microscopy to 1.6-mm 
depth in mouse cortex,” J. Biomed. Opt. 16, 106014 (2011). 
10. N. Ji, D. E. Milkie, and E. Betzig, “Adaptive optics via pupil segmentation for high-
resolution imaging in biological tissues,” Nat. Methods 7, 141-147 (2010). 
11. M. Rueckel, J. A. Mack-Bucher, and W. Denk, “Adaptive wavefront correction in 
two-photon microscopy using coherence-gated wavefront sensing,” Proc. Natl. Acad. Sci. U.S.A. 
103, 17137-17142 (2006) 
12. A. Leray, K. Lillis, and J. Mertz, “Enhanced background rejection in thick tissue 
with differential-aberration two-photon microscopy,” Biophys. J. 94, 1449-1458 (2008). 
13. M. A. A. Neil, R. Juskaitis, and T. Wilson, “Method of obtaining optical sectioning 
by using structured light in a conventional microscope,” Opt. Lett. 22, 1905-1907 (1997). 
14. Z. Yaqoob, D. Psaltis, M. S. Feld, and C. Yang, “Optical phase conjugation for 
turbidity suppression in biological samples,” Nat. Photonics 2, 110-115 (2008). 
28 
 
15. G. Zhu, J. v. Howe, M. Durst, W. Zipfel, and C. Xu, Simultaneous Spatial and 
Temporal Focusing of Femtosecond Pulses (Conference on Lasers and Electro-Optics (CLEO), 
2005). 
16. N. Chen, Chee-Howe Wong, and C. J. Sheppard, “Focal modulation microscopy,” 
Opt. Express 16, 18764-18769 (2008). 
17. J. B. Ding, K. T. Takasaki, and B. L. Sabatini, “Supraresolution imaging in brain 
slices using stimulated-emission depletion two-photon laser scanning microscopy,” Neuron 63, 
429–437 (2009). 
18. B. Paolo, B. Harke, S. Galiani, G. Vicidomini, and A. Diaspro, “Single-wavelength 
two-photon excitation-stimulated emission depletion (SW2FE-STED) superresolution imaging,” 
Proc. Natl. Acad. Sci. U.S.A. 109, 6390-6393 (2012). 
19. E. Betzig, G. H. Patterson, R. Sougrat, O. W. Lindwasser, S. Olenych, J. S. 
Bonifacino, M. W. Davidson, J. Lippincott-Schwartz, and H. F. Hess, “Imaging intracellular 
fluorescent proteins at nanometer resolution,” Science 313, 1642-1645 (2006). 
20. M. J. Rust, M. Bates, and X. Zhuang, “Sub-diffraction-limit imaging by stochastic 
optical reconstruction microscopy (STORM),” Nat. Methods 3, 793-795 (2006). 
29 
 
21. M. G. L. Gustafsson, “Nonlinear structured-illumination microscopy: wide-field 
fluorescence imaging with theoretically unlimited resolution,” Proc. Natl. Acad. Sci. U.S.A. 
102,13081–13086 (2005). 
22. T. Dertinger, R. Colyer, G. Iyer, S. Weiss, and J. Enderlein, “Fast, background-free, 
3D super-resolution optical fluctuation imaging (SOFI),” Proc. Natl. Acad. Sci. U.S.A. 106, 
22287–22292 (2009). 
23. S. W. Hell and J. Wichmann, “Breaking the diffraction resolution limit by 
stimulated emission: stimulated-emission-depletion fluorescence microscopy,” Opt. Letters 19, 
780-782 (1994). 
24. S. Berning, K. I. Willig, H. Steffens, P. Dibaj, and S. W. Hell, “Nanoscopy in a 
living mouse brain,” Science 335, 551 (2012). 
25. M. Beutler, K. Makrogianneli, R. J. Vermeij, M. Keppler, T. Ng, T. M. Jovin, and 
R. Heintzmann, “satFRET: estimation of Forster resonance energy transfer by acceptor saturation,” 
Eur. Biophys. J. 38, 69–82 (2008). 
26. P. E. Htiinen, L. Lehtelii, and S. W. Hell, “Two- and multiphoton excitation of 
conjugate-dyes using a continuous wave laser,” Opt. Commun. 130, 29-33 (1996). 
30 
 
27. A. Schonle, P. E. Hanninen, and S. W. Hell, “Nonlinear fluorescence through 
intermolecular energy transfer and resolution increase in fluorescence microscopy,” Ann. Phys. 8, 
115-133 (1999). 
28. C. I. Richards, J. Hsiang, A. M. Khalil, N. P. Hull, and R. M. Dickson, “FRET-
enabled optical modulation for high sensitivity fluorescence imaging,” J. Am. Chem. Soc. 132, 
6318-6323 (2010). 
29. K. Fujita, M. Kobayashi, S. Kawano, M. Yamanaka, and S. Kawata, “High-
resolution confocal microscopy by saturated excitation of fluorescence,” Phys. Rev. Lett. 99, 
228105 (2007). 
30. J. Lukomska, I. Gryczynski, J. Malicka, S. Makowiec, J. R. Lakowicz, and Z. 
Gryczynski, “Two-photon induced fluorescence of Cy5-DNA in buffer solution and on silver 
island films,” Biochem. Biophys. Res. Commun. 328, 78-84 (2005). 
31. W. R. Zipfel, R. M. Williams, and W. W. Webb, “Nonlinear magic: multiphoton 
microscopy in the bioscience,” Nat. Biotechnol. 21, 1369-1377 (2003). 
32. Y.-T. Kao, X. Zhu, F. Xu, and W. Min, “Focal swithching of photochromic 
fluorescent proteins enables multiphoton microscopy with superior image contrast,” Biomed. Opt. 
Express 3, 1955-1963 (2012). 
31 
 
33. Z. Chen, L. Wei, X. Zhu, and W. Min, "Extending the fundamental imaging-depth 
limit of multi-photon microscopy by imaging with photo-activatable fluorophores," Opt. Express 
20, 18525-18536 (2012) 
34. X. Zhu, Y.-T. Kao and, W. Min, “Molecular-switch-mediated multiphoton 




Bioluminescence Assisted Switching and Fluorescence Imaging 
(BASFI) 
Förster resonance energy transfer (FRET) and bioluminescence resonance energy transfer 
(BRET) are two major biophysical techniques for studying nanometer-scale motion dynamics 
within living cells. Both techniques read photoemission from the transient RET-excited acceptor, 
which makes RET and detection processes inseparable. In this chapter, we report a novel hybrid 
strategy, bioluminescence assisted switching and fluorescence imaging (BASFI) using a 
bioluminescence Renilla luciferase RLuc8 as the donor and a photochromic fluorescent protein 
Dronpa as the acceptor. When in close proximity, RET from RLuc8 switches Dronpa from its 
original dark state to a stable bright state, whose fluorescence is imaged subsequently with an 
external laser. Such decoupling between RET and imaging processes in BASFI promises high 
photon flux as in FRET and minimal bleedthroughs as in BRET. We demonstrated BASFI with 
Dronpa-RLuc8 fusion constructs and drug-inducible intermolecular FKBP-FRB protein-protein 
interactions in live cells with high sensitivity, resolution, and specificity. Integrating the 
advantages of FRET and BRET, BASFI will be a valuable tool for various biophysical studies.  
3-1 Introduction  
Resonance Energy Transfer (RET) techniques [1] based on fluorescence (FRET) [2] or 
bioluminescence (BRET) [3] are widely applied for cellular imaging to study fundamental 
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biochemistry. The efficiency of energy transfer is dependent on the sixth order of donor-acceptor 
distance and hence RET methods are sensitive for short-distance (on the nanometer scale) 
interactions/changes. Many biochemical interactions/changes fall within this range. Therefore, 
FRET and BRET are well suited for studies of protein-protein interactions [4,5] as well as protein 
conformation changes that report functionally important cellular contents such as calcium [6], pH 
[7], glucose [8], Cu2+ [9], and so forth.  
In both FRET and BRET, the photoemission from the RET-excited acceptor serves as the 
readout. In FRET, an external laser is employed as the energy source for donor excitation (Scheme 
3-1a, left). In BRET, energy source is provided through luciferase substrate oxidation (Scheme 3-
1a, right). Because of the transient nature of the electronic excited state, photoemission of acceptor 
in both FRET and BRET is collected concurrently as RET occurs.  
We here propose a novel hybrid RET strategy, bioluminescence-assisted switching and 
fluorescence imaging (BASFI), using a bioluminescence donor and a photoswitchable fluorescent 
protein as its acceptor. Photoswitchable proteins such as Dronpa (DG1) are an emerging class of 
fluorescence proteins that can undergo reversible photoswitching [10, 11], between a bright 
fluorescent state and a dark state via chromophore isomerization. This unique property has enable 
tremendous advances in frontier imaging techniques, such as super-resolution imaging [12], deep-
tissue imaging [13-16] biosensors [17], and optical control [18]. Herein we adopt the dark state 
DG1 as the energy acceptor of a bioluminescent protein RLuc8. The photophysics involved in 
BASFI is illustrated in Scheme 3-1b. Bioluminescence energy transfer from RLuc8 excites the 
dark-state DG1, which isomerizes to a bright state. This bright state population is thermally stable 
and does not relax back to dark state. Therefore, as the bioluminescence and RET continues, the 
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population of bright state DG1 accumulates. We subsequently image this bright state population 
with an external with an external laser that excites the DG1 only. In this way, the RET process and 
imaging process are temporally decoupled. We demonstrated the principle of BASFI and applied 
it in imaging of intramolecular and intermolecular protein-protein interactions (PPI). In both cases 
BASFI can achieve both the high sensitivity of FRET and the minimal spectral bleedthrough of 
BRET.  
     Scheme 3-1: Photophysics Involved in FRET, BRET and BASFI   
              
As in FRET and BRET, donor and acceptor spectral overlap is critical in BASFI. In 
equilibrium, DG1 is mainly in its bright state, which emits green fluorescence when excited at 




switched back to the bright state by violet light around 400 nm. As the switching-on quantum yield 
of DG1 is much higher than the switching-off yield, we naturally harness its efficient on-switching 
process in our BASFI design. To match the absorption spectrum of the DG1 dark state, we 
specifically chose BRET2 [19,20] enzyme and substrate that luminesces around 400 nm as the 
donor (while the BRET1 system luminesces around 490 nm [21]). After absorbing ET from RLuc8, 
the dark state of DG1 can be switched to its bright state, which can then be subsequently imaged 
with an external laser (Scheme 3-1b).  
             
Fig. 3-1. Bioluminescence spectra and reaction kinetics of different substrates catalyzed by RLuc8. 
Reactions were carried out in cell lysates of RLuc8-expecting HEK293T cells mixed with 5 µM 
substrates. (a) Bioluminescence spectra. The peaks of substrates are indicated in the legend. The 
absorption spectrum of DG1 dark state also overlaid. (b) Bioluminescence kinetics.  
CTZ400a, also referred to as “deep blue C”, used to be the sole RLuc8 substrate that 
luminesces around 400 nm. The luminescence quantum yield of CTZ400a is extremely low. We 
here present three new (CTZ analogues, me-CTZ, me-eCTZ, and me-eCTZf, from Nanolight 
Technology (“me” stands for “methoxy”). Figure 3-1 shows the RLuc8 catalyzed bioluminescence 
spectra and kinetics of these four substrates. The spectra all peak around 400 nm with substantial 
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overlaps with the absorption spectrum of the dark state DG1 (Figure 3-1a). The me- substrates 
exhibit up to 13-fold higher luminescence than CTZ400a (Figure 3-1b). Hence they are good 
candidates for BASFI, as will be shown in the following.  
3-2 Results and Discussion  
We first demonstrate the effectiveness of BASFI in a fusion construct DG1-RLuc8 with an 
optimized 12-amino-acid linker [24] A point mutation S257G was introduced into RLuc8 to 
increase the luminescence yield [25]. We expressed the fusion in HEK293T cells and performed 
BASFI in live cells. The experimental procedure and raw data are illustrated in Scheme 3-2. In 
equilibrium, DG1 is in bright state (Scheme 3-2a), so we first switched off DG1 by scanning with 
a 488 nm laser (Scheme 3-2b), and then substrates were added to the media. We allowed the 
reaction to proceed for 10 min, and then imaged the BRET-switched-on population of DG1 with 
a 514 nm excitation laser (Scheme 3-2c). In order to quantify the extent of BRET facilitated on-
switching, we subsequently switched on all DG1 with a UV lamp and imaged again with the 514 
nm laser (Scheme 3-2d). By comparing these two fluorescence images, we got the BRET-
switched-on population percentage of the bright state (Scheme 3-2e).  
                   Scheme 3-2: BASFI Experimental Procedure*   
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*(a) DG1 is in bright state at equilibrium. (b) DG1 is switched off by a 488 nm laser. (c) Addition 
of RLuc8 substrate switches DG1 to bright state after some time. (d) Exposure to UV light switches 
all DG1 in the cell to bright state. (e) The ratio between the images in (c) and (d) represents the 
percentage of DG1 switched on by BASFI. Scale bar: 10 µm. 
Figure 3-2a-d shows the ratio images of such percentages using various substrates. 
Consistent with their luminescence spectra and yields, me- substrates switch on DG1 more 
effectively than CTZ400a. As expected, when no substrate was used, DG1 remained in the dark 
state (Figure 3-2e). Figure 3-2g further shows the time-dependent kinetics of the bright state 
population every 2 min after addition of substrates, for a total of 10 min.  
 
Fig. 3-2. Live cell intramolecular BASFI of DG1-RLuc8(S257G) in HEK293T cells. (a-d): BRET2-
switched-on percentage of DG1 by RLuc8 after incubating with different substrates for 10 min: (a) 
me-eCTZ; (b) me-eCTZf; (c) me-CTZ; (d) CTZ400a. (e) In the absence of substrates, DG1 stays in 
the dark state. (f) Control images with DG1 alone expressed in HEK293T cell using me-eCTZ (more 
control images using other substrates are shown in Figure S1). Without the donor RLuc8, DG1 
cannot be switched on. (g) Kinetics of BASFI. Each data point is an average of three cells. The error 




Both the images and the kinetics of BASFI presented in Figure 3-2 evidently proved that 
energy transfer has occurred between RLuc8 and DG1 dark state in our intramolecular construct. 
When no substrates were present, the measured bright-state population percentage remained below 
5%, which raises from the residual dark state fluorescence [10]. When proper substrates were 
added, bright state population kept increasing as bioluminescence reaction continued. After 10 min, 
more than 50% DG1 was switched on, yielding a signal-to-background ratio of more than 10. 
Among the four substrates tested, me-eCTZ outperformed the rest, because of its highest 
luminescence yield (Figure 3-1b) and the plausible better spatial orientation between the enzyme-
bound me-eCTZ and dark state DG1. For additional controls, we did similar experiments on DG1 
alone with me-eCTZ as shown in Figure 3-2f and other substrates in Figure 3-3. Without the donor 







Fig. 3-3. Control experimental to Fig 3-2. When DG1 alone is expressed in HEK293T, in the 





To further validate that the observed fluorescence increase is solely the consequence of 
BASFI instead of other factors including bioluminescence or DG1 switching-on by long-range 
scattering luminescence photons, we first performed control experiments with RLuc8 (without 
DG1) expressed in HEK293T cell (Figure 3-4). No signal can be detected when substrates were 
added to these cells. Therefore, the detected signal could not have been bioluminescence. We then 
co-expressed unlinked RLuc8 and DG1 in HEK293T cells (Figure 3-5). No significant increase of 
fluorescence signal was observed after addition of substrates. Therefore, when RLuc8 and DG1 
are not fused together, no energy transfer occurred between them, and DG1 could not be switched 
on by scattering bioluminescence photons.  
            
Fig. 3-4. Images of HEK293T cells expressing RLuc8 alone (no DG1). Different substrates were 
added to cells and three sets of data were taken for each substrate. All experimental procedures were 
same as in the main text. Images (a) – (e) are: DIC (a), before 488 nm scanning (b), immediately 
after 488 nm scanning (c), 10’ after addition of substrate (d), and after shining with UV lamp (e). 




                   
Fig. 3-5. Images of HEK293T cells co-expressing unlinked RLuc8 and DG1. Different substrates 
were added to cells and three sets of data were taken for each substrate. All experimental procedures 
were same as in the main text. Images (a) – (e) are: DIC (a), before 488 nm scanning (b), 
immediately after 488 nm scanning (c), 10’ after addition of substrate (d), and after shining with 
UV lamp (e). Although bioluminescence is visible by naked eye, no DG1 was switched on by 
scattering bioluminescence photons.   
We next determined the interaction range between RLuc8 and DG1. We carried out 
systematic distance-dependence study of the BASFI efficiency. We fused DG1 to RLuc8 with 
varying linker lengths. The linkers are (GGSGGS) sequence repeats of 1 to 6 adopted from 
previous studies [26, 27]. The peptide length increases 3 Å with every one additional (GGSGGS) 
sequence as estimated by computer simulation with a worm like chain model. We transfected these 
constructs in HEK293T cells, added 25 µM me-CTZ and measured BASFI efficiency. Ratio 
images showing BASFI efficiency are shown in Figure 3-6a. One can see that with increasing 
linker length, the BASFI efficiency gradually decreases. With 6 data points of BASFI efficiency 




(Figure 3-6b). This is close to the typical Förster distance between popular GFP FRET pairs [28]. 
It falls within common protein conformation change ranges and protein-protein interaction ranges, 
which BASFI would be suited for. 
 
Fig. 3-6. Donor-acceptor distance dependence of BASFI efficiency. (a) Linker length between 
RLuc8 and DG1 is varied by inserting 1-6 repeats of (GGSGGS) sequence. Three images are shown 
for each constructs. Substrate used here is 25 µM me-CTZ. Schematic distance change is illustrated 
on the top. RLuc8 is shown in cyan color and DG1 in green. Red loop is the linker. (b) Measured 
raw data of BASFI efficiency is modeled with Förster equation to deduce R0 = 45 Å. Three cells are 
measured for each distance. Error bars are standard deviations. Scale bar: 10 µm.  
 Finally, we demonstrated that BASFI works well for detection of intermolecular PPI in 
live cells. As a proof of principle, we chose the well-studied rapamycin (Rap) regulated association 
of proteins FKBP and FRB as a model system [29]. We adopt a chimeric Lyn11-FKBP-FKBP (L-
FKBP2) construct that is highly effective in heterodimerization with FRB in the presence of Rap 
[30], where Lyn11 (L) is a plasma membrane localization sequence. We then fused RLuc8 to the 
C-terminus of L-FKBP2, and fused DG1 to the N-terminus of FRB. We termed the resulting 
constructs as L-FKBP2-RLuc8 and DG1-FRB in HEK293T cells. When Rap was present, as 
42 
 
shown in Figure 3-7a-d, after substrates were added, we observed obvious BRET facilitated 
switching-on of DG1 in the plasma membrane region, which clearly proves that DG1-FRB was 
attracted to the membrane localized L-FKBP2-RLuc8 and formed heterodimer there. Cytosolic 
population of DG1 is simply too low to be detected.  
 
Fig. 3-7. Live cell intermolecular BASFI of Rap induced L-FKBP2-RLuc8 and DG1-FRB 
association in HEK293T cells. (a-d) Ratio images of BRET2-switched-on population of DG1 after 
incubating with different substrates for 10 min: (a) me-eCTZ; (b) me-eCTZf; (c) me-CTZ; (d) 
CTZ400a. (e) Control images without addition of substrates. (f) Control images without Rap, using 
the substrate me-eCTZ (more control images with other substrates are shown in Figure 3-8). (g) 
Kinetics of intermolecular BASFI measured from the membrane region. Each data point is an 
average of three cells. Error bars are standard deviations. Scale bar: 10 µm. 
As one negative control, in the absence of any substrates but in the presence of Rap, DG1-
FRB can be observed on the cell membrane but with extremely low bright-state switching 
population (Figure 3-7e). As another negative control, for cells without adding Rap but with 
substrate me-eCTZ, DG1-FRB is observed to be homogeneously distributed throughout the 




This observation is consistent with the known fact that Rap is required to induce PPI between 
FKBP and FRB. Furthermore, Figure 7g shows the detailed kinetics of the bright-state of DG1 
every 2 min in the presence of Rap after addition of various substrates. More kinetics curves of 
control experiments without Rap are shown in Figure 8. DG1 bright state population increases 
when both Rap and proper substrates are present, but remains below baseline when there is no Rap 
or substrate. Therefore, BASFI demonstrates high specificity in imaging subcellular PPI as 
exemplified by FKBP and FRB.  
Fig. 3-8. Control experimental to Fig 3-7. L-FKBP2-RLuc8 and DG1-FRB were co-expressed in 
HEK293T cells. In the absence of rapamycin, addition of substrate cannot switch DG1 on.  
3-3 Experimental Methods 
pcDNA-RLuc8 containing the cDNA of RLuc8 was generously provided by Dr. Sanjiv 
Sam Gambhir at Stanford University. Plasmid L-FKBP2-CFP and pEGFP-FRB were purchased 





Inc. by replacing the CFP and EGFP with RLuc8 and DG1 gene, respectively. All DG1 and RLuc8 
fusion constructs were custom-made in GenScript.  
All substrates were purchased from Prolume Ltd. (http://nanolight.com). Substrates were 
dissolved in propylene glycol to a concentration of 5 mM and then stored in a -80 ˚C freezer in 1 
µL aliquots. To measure the bioluminescence spectra and kinetics, pcDNA-RLuc8 was expressed 
in HEK293T cells for 48 h, and then was lysed with 1X passive lysis buffer (Promega). Then 
substrates were added to a final concentration of 5 µM. Luminescence was immediately collected 
in a BioTek synergy 4 hybrid multimode microplate reader. For the bioluminescence spectra, 
signal was collected every 2 nm with an integration time of 0.1 s. For the kinetics, signal was 
collected every 2 s with no filter and an integration time of 1 s.  
For BASFI imaging, HEK293T were seeded in Lab-Tek 8-well chambers with glass 
bottom in a medium composed of 90% DMEM, 10% FBS and 1% penicillin/streptomycin. 
Plasmids were expressed in HEK293T for 48 h. Then medium was replaced with 1X PBS buffer 
of pH6.8 right before imaging. Images were collected in Leica TCS SP5 confocal microscope. A 
63X 1.2 N.A. water immersion objective was used in all experimental procedures. DG1 was first 
switched off to the dark state by 5 scans of 488 nm laser with a dwell time of 200 µs. The power 
of 488 nm laser was 12.7 µW as measure from the front aperture of the objective. Then substrates 
were manually added into the sample wells to a final 25 µM. Images were taken either every 2 min 
or after 10 min with a 514 nm laser of 0.7 µW, dwell time 40 µs. Fluorescence of DG1 was 
collected from 520 to 650 nm. Then sample was shined with the UV lamp for 10 s, and an image 
of 514 nm excitation was taken again. Images of DG1 population percentage were generated by 
directly dividing images following addition of substrates to that after exposure to UV.  
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3-4 Conclusion and perspectives 
We have presented here a novel hybrid RET method, BASFI, that can identify protein-
protein interactions in live cells with high sensitivity, specificity, and resolution. We exploit the 
transition of DG1 chromophore from dark to bright state on accepting energy around 400 nm. This 
transition is fundamentally different from those involved in traditional FRET or BRET. In 
traditional FRET or BRET, energy transfer excites the acceptor to its transient electronic excited 
state, which quickly returns to its ground site within nanoseconds via spontaneous emission. As a 
result, the RET-sensitized excitation and the RET are occurring. In BASFI, energy transfer drives 
DG1 chromophore isomerization from its dark state to its bright state (both are stable electronic 
ground states). Unlike the short-lived electronic excited state, the switched-on bright state of DG1 
does not relax back to the dark state, and its population steadily accumulates over time as 
bioluminescence continues. As a result, there is no urgency to image this bright state concurrently 
as RET occurs. Instead laser in a fluorescence microscope with high photon flux. Therefore, the 
imaging process is decoupled process in BASFI.  
Such decoupling of RET and imaging in BASFI could significantly reduce spectral 
bleedthrough in FRET and elevate photon flux in BRET. As a comparison, we measured the donor 
and acceptor bleedthroughs in the widely used CFP-YFP FRET pair (Figure 3-9) and determined 
donor bleedthrough (DBT) and acceptor bleedthrough (ABT) to be >40% and >10%, respectively. 
These numbers are much larger than the 5% baseline present in BASFI. Three different samples 
and seven images are required to correct for these bleedthroughs in FRET. Moreover, typical 
FRET efficiency is ~10% (Figure 3-9d) and signal-to-background ratio is less than 1. BASFI 
efficiency is up to 50% and signal-to-background ratio is up to 10. Note that by using 
46 
 
photoswitchable fluorescent proteins that have less dark state fluorescence, such as mGeos [31], 
the 5% baseline of DG1 could be further reduced and thus the signal-to-background ratio can be 
even higher. Meanwhile, external laser excitation of acceptor in BASFI which is limited by the 
slow enzyme turnovers. As a result, as demonstrated in FKBP-FRB interaction, BASFI is capable 
of subcellular imaging, which is difficult to achieve with BRET.  
     
 
Fig. 3-9. Severe spectral bleedthroughs present in CFP-YFP pair. We performed typical 
FRET imaging using the CFP-YFP pair to get the values of spectral bleedthroughs and FRET 
efficiency in a similar PPI system, the rapamycin (Rap) induced FKBP-FRB interaction. (a) and (b): 
images of HEK293T cells expressing CFP-FKBP (donor, a) or YFP-FRB (acceptor, b) only. FRET 
channel: donor excitation at 458 nm and acceptor detection of 520-580 nm. Donor channel: donor 
excitation at 458 nm and donor detection at 462-510 nm. Acceptor channel: acceptor excitation at 
514 nm and acceptor detection at 520-580 nm. The bleedthrough percentages are calculated as the 




donor and acceptor bleedthroughs for the cells in (a) and (b). Average donor bleedthrough is > 40%. 
Average acceptor bleedthrough is > 10%. (d) FRET efficiency of Rap-inducible interaction between 
CFP-FKBP and YFP-FRB. Both conditions with or without Rap are shown. The FRET efficiency 
is ~ 10%. 
We believe the same strategy should also be applicable to studies of other close-range 
interactions in live cells such as protein conformation change, enzymatic dynamics, and so forth. 
With the future development of more efficient luciferases, brighter substrates, and faster switching 





1. M. J. Lohse, S. Nuber, and C. Hoffmann, “Fluorescence/bioluminescence 
resonance energy transfer techniques to study G-protein-coupled receptor activation and 
signaling”, Pharmacol. Rev. 64, 299-336, (2012). 
2. A. Miyawaki, “Development of probes for cellular functions using fluorescent 
proteins and fluorescence resonance energy transfer”, Annu. Rev. Biochem.  248, 73-76 (2011). 
3. D. K. Welsh and T. Noguchi, “Cellular bioluminescence imaging”, In Cold Spring 
Harbor Protocols, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 8, 357-373 
(2012). 
4. M. A. Lowder, J. S. Appelbaum, E. M. Hobert, and A. Schepartz, “Visualizing 
protein partnerships in living cells and organisms”, Curr. Opin. Chem. Biol. 15, 781-788 (2011). 
5. V. Coulon, M. Audet, V. Homburger, J. I. Bockaert, L. Fagni, M. Bouvier, and J. 
Perroy, “Subcellular imaging of dynamic protein interactions by bioluminescence resonance 
energy transfer”, Biophys. J. 94, 1001-1009 (2008) 
6. A. Miyawaki, J. Llopis, R. Heim, J. M. McCaffery, J. A. Adams, M. Ikura, and R. 
Y. Tsien, “Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin”, 
Nature, 388, 882-887 (1997) 
49 
 
7. A. Esposito, M. Gralle, M. A. C. Dani, D. Lange, and F. S. Wouters, “pHlameleons: 
a family of BRET-based protein sensors for quantitative pH imaging”, Biochemistry, 47, 13115-
13126 (2008). 
8. H. Takanaga, B. Chaudhuri, and W. B. Frommer, “GLUT1 and GLUT9 as major 
contributors to glucose influx in HepG2 cells identified by a high sensitivity intramolecular FRET 
glucose sensor”, Biochem. Biophys. Acta, 1778, 1091-1099 (2008). 
9. H. J. Kim, S. Y. Park, S. Yoon, and J. S. Kim, “FRET-derived ratiometric 
fluorescence sensor for Cu2+”, Tetrahedron 64, 1294-1300 (2008). 
10. R. Ando, H. Mizuno, and A. Miyawaki, “regulated fast nucleocytoplasmic shuttling 
observed by reversible protein high-lighting”, Science 306, 1370-1373 (2004).  
11. X. X. Zhou and M. Z. Lin, “Photoswitchable fluorescent proteins: ten years of 
colorful chemistry and exciting applications”, Curr. Opin. Chem. Biol. 17, 682-690 (2013). 
12. H. Shroff, C. G. Galbraith, J. A. Galbraith, H. White, J. Gillette, S. Olenych, M. W. 
Davidson, and E. Betzig, “Dual-color super-resolution imaging of genetically expressed probes 
within individual adhesion complexes”, Proc. Natl. Acad. Sci. U.S.A. 104, 20308-20313 (2007). 
13. Y.-T Kao, X. Zhu, F. Xu, and W. Min, “Focal switching of photochromic 
fluorescent proteins enables multiphoton microscopy with superior image contrast”, Biomed. Opt. 
Express 3, 1955-1963 (2012). 
50 
 
14. X. Zhu, Y.-T. Kao and W. Min, “Molecular-switch-mediated multiphoton 
fluorescence microscopy with high-order nonlinearity”, J. Phys. Chem. Lett. 3, 2082-2086 (2012). 
15. L. Wei, Z. Chen, and W. Min, “Stimulated emission reduced fluorescence 
microscopy: a concept for extending the fundamental depth limit of two-photon fluorescence 
imaging”, Biomed. Opt. Express 3, 1465-1475 (2012). 
16. Z. Chen, L. Wei, X. Zhu, and W. Min, “Extending the fundamental imaging-depth 
limit of multi-photon microscopy by imaging with photo-activatable fluorescence”, Opt. Express 
20, 18525-18536 (2012). 
17. Y.-T. Kao, X. Zhu, and W. Min, “Protein-flexibility mediated coupling between 
photoswitching kinetics and surrounding viscosity of a photochromic fluorescent protein,” Proc. 
Natl. Acad. Sci. U.S.A. 109, 3220-3225 (2012). 
18. X. X. Zhou, H. K. Chung, A. J. Lam, and M. Z. Lin, “Optical control of protein 
activity by fluorescent protein domains,” Science 338, 810-814 (2012). 
19. L. Bertrand, S. Parent, M. Caron, M. Legault, E. Joly, S. Angers, M. Bouvier, M. 
Brown, B. Houle, L. Menard, “The BRET2/arrestin assay in stable recombinant cells: a platform 
to screen for compounds that interact with G protein-coupled receptors (GPCRs),” J. Recept. 
Signal Transduction Res. 22, 533-541 (2002). 
51 
 
20. A. De, and S. S. Gambhir, “Noninvasive imaging of protein-protein interactions 
from live cells and living subjects using bioluminescence resonance energy transfer,” FASEB J. 
19, 2017-2019 (2005). 
21. Y. Xu, D. W. Piston, and C. H. Johnson, “Bioluminescence resonance energy 
transfer (BRET) system: application to interacting circadian clock proteins,” Proc. Natl. Acad. Sci. 
U.S.A. 96, 151-156 (1999). 
22. A. M. Loening, T. D. Fenn, A. M. Wu, and S. S. Gambhir, “Consensus guided 
mutagenesis of renilla luciferase yields enhanced stability and light output,” Protein Eng., Des. 
Sel. 19, 391-400 (2006). 
23. A. M. Loening, A. M. Wu, S. S. Gambhir, “Red-shifted renilla reniformis luciferase 
variants for imaging in living subjects,” Nat. Methods 4, 641-643 (2007). 
24. H. Hoshino, Y. Nakajima, and Y. Ohmiya, “Luciferase-YFP fusion tag with 
enhanced emission for signal-cell luminescence imaging,” Nat. Methods 4, 637-639 (2007). 
25. K. Saito, Y. F. Chang, K. Horikawa, N. Hatsugai, Y. Higuchi, M. Hashida, Y. 
Yoshida, T. Matsuda, Y. Arai, and T. Nagai, “Luminescent proteins for high-speed signal-cell and 
whole-body imaging,” Nat. Commun. 3, 1262 (2012). 
52 
 
26. T. H. Evers, E. M. W. M. van Dongen, A. C. Faeson, E. W. and Meijer, M. Merkx, 
“Quantitative understanding of the energy transfer between fluorescent proteins connected via 
flexible peptide linkers,” Biochemistry 45, 13183-13192 (2006). 
27. E. M. W. M. van Dongen, T. H. Evers, L. M. Dekkers, E. W. Meijer, L. W. J. 
Klomp, and M. Merkx, “Variation of linker length in ratiometric fluorescent sensor proteins allows 
rational tuning of Zn (II) affinity in the picomolar to femtomolar range,” J. Am. Chem. Soc. 129, 
3494-3495 (2007). 
28. A. J. Lam, F. St-Pierre, Y. Gong, J. D. Marshall, P. J. Cranfill, M. A. Baird, M. R. 
McKeown, J. Wiedenmann, M. W. Davidson, M. J. Schnitzer, et al, “Improving FRET dynamic 
range with bright green and red fluorescent proteins,” Nat. Methods 9, 1005-1012 (2012). 
29. J. Chen, X. F. Zheng, E. J. Brown, and S. L. Schreiber, “Identification of an 11-
kDa FKBP12-Rapamycin-binding domain within the 289-kDa FKBP12-Rapamycin-associated 
protein and characterization of a critical serine residue,” Proc. Natl. Acad. Sci. 92, 4947-4951 
(1995). 
30. T. Inoue, W. Do Heo, J. S. Grimley, T. J. Wandless, and T. Meyer, “An inducible 
translocation strategy to rapidly activate and inhibit small GTPase signaling pathways,” Nat. 
Methods 2, 415-418 (2005). 
53 
 
31. H. Chang, M. Zhang, W. Ji, J. Chen, Y. Zhang, B. Liu, J. Lu, J. Zhang, P. Xu, and 
T. Xu, “A unique series of reversibly switchable fluorescent proteins with beneficial properties for 







Free Energy Perturbation Calculation of Relative Binding Free 
Energy between Broadly Neutralizing Antibodies and the gp120 
Glycoprotein of HIV-1 
Direct calculation of relative binding affinities between antibodies and antigens is a long-
sought goal. However, despite substantial efforts, no generally applicable computational method 
has been described. Chapter 4 describes a systematic free energy perturbation (FEP) protocol and 
calculate the binding affinities between the gp120 envelope glycoprotein of HIV-1 and three 
broadly neutralizing antibodies (bNAbs) of the VRC01 class. The protocol has been adapted from 
successful studies of small molecules to address the challenges associated with modeling protein-
protein interactions. Specifically, we built homology models of the three antibody-gp120 
complexes, extended the sampling times for large bulky residues, incorporated the modeling of 
glycans on the surface of gp120 and utilized continuum solvent-based loop prediction protocols to 
improve sampling. We present three experimental surface plasmon resonance data sets, in which 
antibody residues in the antibody/gp120 interface were systematically mutated to alanine. The 
RMS error in the large set (55 total cases) of FEP tests as compared to these experiments, 0.68 
kcal/mol, is near experimental accuracy, and it compares favorably with the results obtained from 
a simpler, empirical methodology. The correlation coefficient for the combined data set including 
residues with glycan contacts, R2 = 0.49, should be sufficient to guide the choice of residues for 
antibody optimization projects, assuming that this level of accuracy to guide the choice of residues 
for antibody optimization projects, assuming that this level of accuracy can be realized in 
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prospective prediction. More generally, these results are encouraging with regard to the possibility 
of using an FEP approach to calculate the magnitude of protein-protein binding affinities.  
4-1 Introduction 
Over the past several years, there has been great interest in the use of broadly neutralizing 
antibodies (bNAbs) for both treatment and prophylaxis against HIV-1 infection [1–6]. About 50% 
of HIV-1 infected individuals produce antibodies with considerable neutralization breadth for a 
wide range of circulating HIV-1 strains after about five years of chronic infection [1,2,7,8].  
However, as isolated from infected donors, most bNAbs would require high dosing to achieve 
efficacy.  For example, human studies with the VRC01 antibody, which neutralizes ~90% of tested 
HIV-1 strains, utilized a minimal therapeutic dosage of 5mg/kg of body weight [9]. Nevertheless, 
bNAbs represent a useful starting point for the development of suitable therapeutic and 
prophylactic agents. 
Numerous HIV-1-neutralizing antibodies, including VRC01 [10], are directed against the 
gp120 surface glycoprotein, the major cell surface extracellular component of the HIV viral spike 
[3].  VRC01 is directed against the initial binding surface on gp120 recognized by the CD4 receptor 
on human host cells [11], a well-characterized site of HIV-1 vulnerability to antibody mediated 
neutralization [12]. In VRC01, recognition of the CD4 binding site (CD4bs) is dominated by the 
antibody second heavy chain complementarity-determining region (CDR H2) [11]. VRC01 is the 
founding member of a class of related antibodies, the VRC01 class [13], which is characterized by 
precise targeting of CD4-binding site [11], genetic signatures including its derivation from the 
VH1-2 heavy chain gene, CDR L3 loops restricted to precisely 5 amino acids in length, and high 
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levels of somatic hypermutation (>30%) for effective neutralizers [4,13].  VRC01-class antibodies 
have been found in numerous donors with broadly neutralizing sera, and the recognition of gp120 
by antibodies from diverse VRC01-class donors is similar [13].  
Over the past several years, there have been extensive efforts to optimize antibody potency 
for a number of bNAbs [14–16].  While experimental optimizations of antibodies can examine a 
large number of potential candidates, they lack the flexibility to efficiently perform a wide 
exploration of possible bNAb mutants.  Computational approaches can in principle complement 
experimental efforts by allowing an investigation of diverse combinations of mutation sites.  For 
computation to make a useful impact, however, a high degree of accuracy and reliability in binding 
affinity prediction, coupled with a tractable computational cost, is required. Given the complexity 
of the gp120/antibody interface, this appears to be a daunting task, which is possibly outside of the 
realm of feasibility for current state-of-the-art computational chemistry technology. 
All atom, explicit solvent-based free energy perturbation (FEP) methods [17,18], 
employing molecular dynamics (MD) simulation methodology, constitute the most rigorous 
physics-based approach to the computation of binding free energies in complex biological systems. 
Historically, it has been difficult to perform accurate, converged FEP simulations, due to 
inadequate computing power, errors in molecular mechanics force fields, and inability of sampling 
algorithms to escape from local minima [19–21].  Over the past decade, these problems have been 
effectively addressed: the first by Moore’s law and the advent of the use of graphics processing 
units (GPUs) for computation, the second by major improvements in force field quality, and the 
third by advanced sampling algorithms such as the replica exchange solute tempering (REST) 
method, which employs a version of local heating to enhance sampling in the region of the 
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perturbation [17,22,23].  In a recent publication, we have shown that for the binding of small-
molecule ligands to a variety of pharmaceutically interesting target proteins, our current FEP 
implementation is capable of achieving an RMS error (RMSE) on the order of 1 kcal/mol, using a 
tractable amount of GPU resources [18].  These results have established FEP as a practical 
methodology for structure-based drug discovery projects. 
While the use of FEP to assess protein-small-molecule ligand binding affinities has a long 
history, there have been relatively few attempts to apply the methodology to the calculation of 
protein-protein binding [24–26].  The interface between two proteins is typically larger and 
significantly more complex than that between a protein and a small molecule ligand, suggesting 
that the sampling effort required to reliably converge such FEP calculations might well be 
substantially larger than that for protein-small-molecule binding.  On the other hand, the results 
should depend only on the quality of the protein force field, so that the small-molecule ligand force 
field (for which it is quite challenging to attain robust coverage of chemical space) is eliminated 
as a possible source of error.  On this basis, one might expect the modeling of protein-protein 
interactions via FEP to be a feasible undertaking, provided that the sampling challenges can be 
surmounted. 
The objective of the present paper is to investigate the use of FEP methodology in modeling 
the binding of the VRC01-class bNAbs to gp120.  The calculations were compared to alanine-
scanning data in which the effects of antibody interface mutants on gp120 binding were quantified 
by surface plasmon resonance measurements. We attempt to predict the changes in binding free 
energy of antibody-gp120 complexes upon mutation of the various interface residues of the 
antibody using FEP/REST.  Three alanine scan data sets represent three initial antibodies from two 
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different donors (VRC01 and VRC03 from NIAID donor 45 [10], and VRC-PG04 from IAVI 
donor 74 [4]).  We consider all mutations studied experimentally other than those involving a net 
change in charge; one case is of a residue that is a terminus of its chain in the crystal structure used, 
and four proline mutants which all were found to have experimental changes in binding affinity 
less than 0.5kcal/mol in magnitude. Calculations on prolines would require significant technical 
effort to implement because of the need to alchemically change topologies from a ring structure to 
a linear backbone in such mutations, while mutations involving a change in net charge pose a 
significantly greater challenge to FEP than mutations that do not involve such a change. We and 
others have been developing methods to address changes in net charge [27,28], however, the 
methodology is still in the process of being tested. The total number of test cases, 55 in all, is 
sufficient to draw useful conclusions concerning performance. 
Although the focus of the present effort is on optimizing and evaluating the FEP 
methodology, there are a number of other important issues that must be addressed if the system 
employed in the experiments is to be properly modeled. Firstly, while crystal structures exist for 
the antibodies in complex with gp120, the binding experiments were performed with a gp120 
variant, which had a slightly different sequence than the one that was crystallized. This necessitated 
the construction of a homology model of the complex starting from the crystal structure. Secondly, 
the surface of the gp120 is decorated by numerous glycan residues which are known to be 
important in the biological function of gp120 and in antibody binding.  The characterization of the 
general glycan content has seen some recent progress [29,30], but the precise chemical 
composition of the glycans in the experimental system used to measure binding affinity is not 
known. In an attempt to take glycans into account, we used the fragment of one particularly 
important glycan, NAG776, in the binding region observed in the crystal structure of the gp120 
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proteins used in building the homology models employed in this study. Inclusion of NAG776 is 
critical in obtaining the accurate prediction of free energy changes for a subset of mutations.  
Once these two issues are addressed, the major remaining challenge is modification of the 
standard sampling algorithm developed for small molecules so that it can handle the protein-
protein interface.  In the current study we found one principal requirement to be the use of greatly 
increased simulation times for tryptophan (TRP) residues, which, when mutated to alanine, 
frequently induce relatively large changes in the protein structure due to their considerable bulk. 
A second problem is manifested when a glycine (GLY) residue is mutated to alanine. In this case, 
the larger alanine residue can induce a nontrivial change in the loop on which the residue is located 
and/or surrounding side chains, and the MD algorithm may have difficulty overcoming the 
sampling barriers to properly explore alternate conformations. We address this problem by using 
continuum solvent-based loop prediction methods to generate predictions of the structure after 
mutation, and then by employing these predictions as an initial guess in the FEP simulations. 
From the above, it should be apparent that obtaining experimentally relevant results for the 
systems of interest represents a considerable modeling challenge, beyond simply deploying a 
standardized FEP protocol.  We view the present work as an extensive exploration of the various 
dimensions of the problem, as opposed to a demonstration that a robust, automated protocol is in 
hand, suitable for application to an arbitrary protein-protein interaction problem without 
modification.  With that caveat, the results shown below are quite encouraging with regard to the 
application of FEP methods to the prediction of protein-antibody interactions and specifically to 
modeling bNAbs bound to gp120.  Prospective results, in which the calculations are done prior to 
experimental measurements, will be required to draw stronger conclusions. 
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This chapter is organized as follows. The Results section first presents brief descriptions 
of the bNAbs that were studied, then experimental results for the three antibody/gp120 binding 
affinity data sets followed by comparisons to results obtained with FEP. In addition to reporting 
FEP results run using both a baseline default protocol, and a protocol including several 
improvements, we also present results using a simple empirical model, FoldX [31], which provides 
a reference point from which to assess the value of the more elaborate and computationally 
expensive FEP approach.  The Discussion section considers the successes, failures, and 
uncertainties observed for the data sets investigated, and outlines the efforts that will be needed to 
construct a robust and efficient general methodology for modeling protein-protein interactions.  
The Models and methods section describes models and methodology used to perform the 
calculations, including experimental techniques, homology model building, treatment of glycans, 
loop and side chain predictions, and FEP protocols. Finally, in the Conclusion, we summarize our 
results and discuss future prospects of the approach. 
4-2 Results 
4-2.1 Test systems studied and experimental binding affinities 
Three VRC01-class bNAbs were considered, for which experimental alanine scans with 
quantification of binding affinities using an Octet biosensor were performed (Table 4-1: VRC01 
and VRC03 [10]—members of the same antibody lineage from NIAID donor 45 – and VRC-PG04, 
from IAVI protocol G donor 74 [4]. Briefly, antibodies and mutants were bound to the Octet tip 
surface, and core gp120 were passed over the surface and sensograms recorded. Kds were 
determined by fitting to a 1:1 binding model (See Models and methods).   Estimated binding free 
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energies typically fall within a total uncertainty range of about 0.5 kcal/mol. Figure 4-1 presents 
all of the sites of mutation experimentally studied for each of the three antibodies listed above. 
Table 4-1: Average value of the dissociation constant (KD) over all independent 
trials performed for each. The first line gives KD for the wild type system, and 
subsequent rows list the values obtained with the sequences with the single point 
mutation listed as well as the relative change in gibbs free energy of binding 
converted from the average dissociation constants. The latter values are used in all 
comparisons with the results from FEP in the main text. For cases where multiple 

















VRC01 22 0  VRC03 63 0   
VRC-
PG04 25 0 
Heavy Chain      
I30 21.9 -0.01  R30 59 -0.04   L34 64 0.57 
T33 71.2 0.7  W47 730 1.48   W47 145 1.07 
W47 161.5 1.19  W50 577 1.33   W50 208 1.53 
W50 187.7 1.28  K52 399 1.11   V52B 6 -0.82 
K52 61.93 0.62  L54 69 0.05   T53 6 -0.85 
R53 14.3 -0.27  W55 223 0.76   G54 53 0.46 
G54 2.64 -1.28  G56 114 0.35   V56 128 0.99 
G55 180 1.26  V58 502 1.25   N57 313 1.53 
V57 209.7 1.35  S59 426 1.15   G59 27 0.06 
N58 413.5 1.76  Y60 261 0.86   P61 12 -0.43 
Y59 54.73 0.54  R62 467 1.21   R64 287 1.48 
R61 114.9 0.99  Q63 401 1.11   R71 2,140 2.69 
P62 20.5 -0.05  Q65 157 0.55   R73 17 -0.22 
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Q64 12.5 -0.35  R72 5,090 2.65   D74 7 -0.23 
M69 53.05 0.52  Q76 74 0.09   Y98 54 0.47 
R71 337 1.64  P78 65 0.01   T99 12 -0.43 
V73 134 1.08  P81 56 -0.08   G100 15 -0.27 
Y74 15.75 -0.21   D110 33 -0.38   G100A 9 -0.63 
D99 24.25 0.05  Y111 250 0.83   G100C 34 0.19 
Y100 234 1.42  D114 42 -0.24   G100D 120 0.95 
N100A 141 1.11  F115 371 1.07         
W100B 36350 4.45                
                     
Light chain        
V3 6.09 -0.78  E1 25 -0.57   V3 11 -0.51 
Q27 15 -0.24  Q27 44 -0.22   Y30 160 1.13 
Y28 112.5 0.97  N30 87 0.2   G31 54 0.47 
S30 17.3 -0.15  D49 261 0.86   L91 124 0.97 
Y91 632.7 2.01  F90 15 -0.87   E96 50 0.42 
E96 197 1.31  E91 778 1.51   F97 26 0.02 
 




       
 
 
In this chapter, we consider only mutations of a neutral side chain to alanine. Figure 4-2 
shows the experimentally determined ∆∆G value for the 55 neutral residues included in the test set 
on the binding interface of the three antibodies. Most of these mutations lead to similar or weaker 
Figure 4-1: Antibody-gp120 interface residues of 
VRC01, VRC03, VRC-PG04 antibodies.  Antibody 
binding interface is in surface representation with 
residues colored as follows: Red - ΔΔG > 2kcal/mol, 
Orange – ΔΔG 1 to 2kcal/mol, Yellow ΔΔG 0.5 to 
1kcal/mol, Gray – ΔΔG -0.5 to 0.5kcal/mol, Blue –
ΔΔG < -0.5kcal/mol. with light chain residue numbers 
italicized.  Antibody non-interfacial residues are in 
cartoon representation colored pale blue (heavy chain) 




binding affinity, which is unsurprising given that for the most part, larger residues were mutated 
to alanine. A more extensive description of the experimental protocols, including error estimation, 
is provided in the Models and Methods section below. 
 
Figure 4-2: Sequence comparison for the heavy and light chains of the VRC01, VRC03, and VRC-
PG04 antibodies. Alanine substitutions with resultant experimentally determined antibody gp120 
binding free energy changes are highlighted as follows: Red - ΔΔG > 2kcal/mol, Orange – ΔΔG 1 
to 2kcal/mol, Yellow ΔΔG 0.5 to 1kcal/mol, Gray – ΔΔG -0.5 to 0.5kcal/mol, Blue –ΔΔG < -
0.5kcal/mol. ΔΔG values for cases included in the test set are listed below each mutated residue. 





4-2.2 Model structures for the Three Experimentally Relevant Complexes 
No crystal structures are available for these three antibody in complex with the gp120 
resurfaced stabilized core 3 (RSC3) [10] protein used in the Octet biosensor experiments we report. 
Therefore, a homology model of the RSC3 protein in complex with each antibody was constructed 
from an existing crystal structure for each antibody—the protein data bank (PDB) number 3NGB 
for VRC01, and numbers 3SE8 and 3SE9 for VRC03 and VRC-PG04, respectively.  Further 
details of the model will be given in the Models and methods section.  Aligned comparisons of the 
part of the three antibody sequences that contain residues that contact the gp120 protein in the 
bound complex are presented in Figure 4-2. The structure of the antibody heavy and light chains 
is taken from the crystal structure in each case.  
The gp120 glycoprotein is known to be heavily glycosylated, with glycosylation playing 
an important role in shielding HIV-1 from immune response [11,29,30,33], and in some cases, 
differences in glycan interactions between the wild-type and mutant residues may substantially 
affect the relative binding affinity arising from sequence mutations. Examination of the crystal 
structures identified one glycan fragment, residue N-acetylglucosamine (NAG776, attached to 
glycosylated residue N276), with direct interactions with residues in the binding interface in all 
three of the crystal structures.  While some recent structures have been solved for bNAbs with the 
full glycan structure present [33-37], the structures for the bNAb-gp120 complexes used as 
templates in building homology models for the bNAbs in this study were solved using a truncated 
version of the glycan species (i.e. with a deglycosylated protein), so only a single asparagine-
attached N-acetylglucosamine remained for each glycan.  In contrast, experimental binding affinity 
measurements were performed using a fully glycosylated protein and so glycans had tails 
66 
 
(containing additional sugar residues) attached to the moiety observable in the crystal structure.  
However, it is a reasonable approximation to assume that the interaction of the tail with the protein 
residues is minimal. However the sugar moiety close to the surface represented by NAG776 in the 
crystal structure is likely to interact directly with the bound antibodies, and for this reason,  we use 
the NAG776 core to account for glycan effects on binding. 
NAG776 is sufficiently distant from many of the mutation sites that it is likely to have little 
or no impact on relative binding affinities. Other sites are much closer; in some cases, these are in 
direct contact with the glycan. We used a scoring function to classify each site into one of the three 
categories: close interaction, moderate interaction, and minimal interaction.  The classification 
function, based on atomic contacts, is described in more detail in the Models and Methods section. 
Based on contact scoring of the wild system in a short MD simulation (see Models and Methods 
for further information), 11 residues are classified as having strong interactions (boxed in black in 
Fig. 4-1), 6 residues are classified have moderate interactions (boxed in green in Fig. 4-1, and the 
remaining 38 as having insignificant interactions.  We investigate the effect of the presence of the 
glycan on the strong and moderate interaction cases; results are shown later in this section.  We 
find that large effects are manifested only for strong interaction cases; for the 6 moderate 
interaction cases, the impact of the glycan on free energy changes was around 0.1 kcal/mole change 
in the RMSE, while the net effect on the RMSE for the 11 strong contact cases is more than 1 
kcal/mol.  Based on this evidence, we conclude that it is safe to ignore the glycan for the 
insignificant interaction cases, and have done so in what follows. 
4-2.3 Default Small Molecule FEP Protocol 
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As an initial calibration point, we present results obtained from running the default FEP 
protocol utilized for small molecule binding affinity prediction in ref. [18], with a modestly 
increased simulation time to account for the significantly more complex interface structure. This 
protocol forms the starting point of our methodology; modifications designed to address specific 
problems found in default simulations are described in subsequent sections below. Details of the 
default protocol are given the Models and Methods section. 
In all cases shown here, only the side chain of the residue involved in the mutation is 
included in the REST region.  Control simulations performed without REST on a significant subset 
of mutation cases indicate that the overall effects of this REST scheme in the alanine scan cases 
are small, but at least one case appears to show significant improvement with REST. Since there 
is negligible additional cost in simulation efficiency including REST over FEP alone, it is retained 
in all cases. Each calculation was repeated to reduce random noise arising from the Monte Carlo 
replica exchange algorithm.  The OPLS3 protein force field was used for all simulations [38]. 
Recent tests, reported in ref. [48], have shown that OPLS3 provides state-of-the-art performance 
with regard to protein and peptide stability. Furthermore, small-molecule FEP calculations have 
validated the ability of the force field to properly respond to ligand perturbation.  We note that in 
our comparisons in ref. [48], the CHARMm force field displayed a performance that was very 
similar to OPLS3 and thus would be likely to yield similar results to those presented below. 
The homology models (see the Models and methods section for further details) were used 
to carry out the calculations.  We include the NAG776 glycan residue in the 17 cases identified as 
having close or moderate contacts with the residue being mutated, whereas it is not included for 
the remaining 38 cases. This aspect of the protocol is employed in all of the calculations that follow. 
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Table 4-2 displays the RMS errors and correlation coefficients with the experimental for 
the three data set (VRC01, VRC03, and VRC04) under the default protocol, and the largest outliers 
for each of these data sets. The overall results (particularly those for the VRC03 antibody) are 
significantly degraded from the most recent small molecule data reported in refs. [18].  
Furthermore, assuming robust sampling, one would expect that the RMS error for protein-protein 
interactions should be smaller than for small molecule perturbations, which additionally depend 
upon the quality of the small-molecule force field in representing highly diverse chemistry. 
Table 4-2:  RMSE and correlation coefficients for the default protocol 
 RMSE (kcal/mol) Correlation coefficient Worst outlier 
VRC01 0.64 0.71 L_Y28: 1.61 kcal/mol 
VRC03 1.72 0.23 L_F91: 2.70 kcal/mol 
VRCPG-04 1.18 0.12 H_G54: 3.19 kcal/mol 
combined 1.19 0.28  H_G54: 3.19 kcal/mol 
These results are not surprising, given the considerations discussed above.  The default run 
time of 10 nsec (for each window in each FEP simulation leg) may not be adequate for all of the 
test cases, and some mutations may involve significant changes in loop geometry or local side-
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chain conformations, which necessitate measures going beyond longer run times in order to 
achieve a suitable transition from the initial to final loop structure.  We conclude from this data 
that improvements in the sampling protocol, are needed if the most quantitatively accurate results 
are to be obtained.  In the following section, we outline several such improvements based on 
analysis of the default protocol results.   
4-2.4 Extended Sampling for Trp mutations 
Examination of the largest outliers in the default protocol results revealed that cases in 
which a tryptophan residue was mutated to alanine displayed errors much larger than average.  
This observation leads to the hypothesis that sampling of Trp mutations may require significantly 
longer simulation time. As a simple test of this hypothesis, all tryptophan simulations were 
extended to 100ns. To avoid complicating issues, we consider here the five TRP cases not 
identified as strong glycan contacts.  Two independent 100ns runs are averaged for these cases. 
The reduction of RMSE for this subset resulting from extending the simulation time was dramatic, 
from 1.85 kcal/mol to 0.97 kcal/mol.  Results for individual cases can be found can be found in 
Table 4-3.  
Table 4-3:  Summary of the five TRP -> ALA cases in the data set, which are not 
strong or moderate glycan contact cases 
Case Experimental ∆∆G 10-ns FEP/REST ∆∆G 
100-ns FEP/REST 
∆∆G 
Change in absolute 
error 
VRC01 W100B 4.45 4.39 4.59 0.08 
VRC01 W50 1.28 0.61 0.33 0.28 
VR01 W47 1.19 1.71 1.12 -0.45 
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VRC03 W50 1.33 4.36 2.68 -1.68 
VRC03 W54 0.76 3.46 2.16 -1.30 
Running totals for the free energy change as a function of simulation time are displayed in 
Figure 4-3 and 4-4 for the example cases of the mutation of W50 in VRC03, and W100B in VRC01.  
In four of the five TRP cases, the bound complex simulation leg shows a significant downward 
relaxation in predicted ∆G over the course of the run.  The relaxation process is quite slow, and 
there can be some residual fluctuation in ∆∆G at 100 nsec in some cases.  However, the RMS error 
after 100 nsec, averaged over all cases, is comparable to that for the remainder of the data set, so 
extending the simulations further is unlikely to yield systematically better results given the current 




Figure 4-3: Running free energy for the W50 case on VRC03, averaged over two independent trials 
of both simulation legs.  Slow convergence is observed in the bound complex leg.  
 
Figure 4-4: Running free energy for the W100B case on VRC01 averaged over the 2 independent 
trials that were performed for this case.  Slow convergence time scales are observed for both the 
bound and unbound legs of the simulation 
In the case of VRC01-W100B, the unbound (solvent) leg of the simulation also changes 
significantly with the longer simulation.  The net result is that the longer simulations lead to a 
comparable prediction as opposed to a smaller one.  This was due to the removal of W100B 
allowing a large-scale rearrangement of the CDR H3 loop, which is at the interface of both the 
heavy chain and the antigen and also the antibody heavy and light chains.  This relaxation may 
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take place on an even slower time scale than the 100-ns time scale can fully capture.  It appears 
however that most of the fluctuation in ∆∆G has relaxed by 100ns, and only the intra-antibody 
relaxation is continuing at 100ns, making further extension unlikely to capture more net effect on 
the relative binding affinity. This case will be discussed in further detail in the subsection “Insights 
from FEP trajectories”. 
We next investigate how the NAG776 glycan influenced the 17 cases identified above as 
having close or moderate contact with this moiety. Three sets of results are shown in Table 4-4. 
Firstly, we present the results of the default protocol for each of the 17 cases. Secondly, we present 
results in which the glycan is removed from the structure, still employing the default simulation 
protocol. Finally, results in which is retained, but the simulations are extended to 100 nsec, are 
given. The principal effects are seen for the strong contact cases; those with moderate contact 
evidence primarily relatively small fluctuations when the glycan is deleted or the simulation 
extended. In the strong contact cases, both the glycan presence and extended simulation times, are 
required to achieve good agreement with experiment. Under these conditions, the RMS error of 
the full 17 contact set, 0.77, is only slightly larger than that of the non-contact cases (0.68 kcal/mol).   
              Table 4-4 Information on glycan-contacting cases 
glycan 
score bNAb chain mutation experiment 






9.96 VRC01 heavy Y100 1.42 0.69 1.03 0.7 
10.29 VRC01 light Y91 2.01 1.26 1.67 1.02 
11.76 VRC01 light Y28 0.97 -0.63 0.36 0.28 
4.31 VRC01 light S30 -0.15 0.08 0.57 0.03 
23.01 VRC03 heavy W47 1.48 3.96 3.92 0.23 
19.69 VRC03 heavy F100D 1.07 4.48 4.1 1.63 
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27.69 VRC03 light F91 -0.87 1.84 0.26 0.38 
69.35 VRC03 light F97 0.83 0.79 1.98 0.51 
28.68 
VRC-
PG04 heavy W50 1.28 2.78 -0.71 -0.11 
21.49 
VRC-
PG04 heavy W47 1.07 1.18 -0.35 0.86 
20.28 
VRC-
PG04 heavy G100A -0.63 -0.17 0.14 -0.37 
13.78 
VRC-
PG04 heavy Y98 0.47 1.37 -0.25 -0.02 
4.69 
VRC-
PG04 heavy G100 -0.27 1.12 0.76 0.7 
21.48 
VRC-
PG04 heavy G100C 0.19 0.07 -0.11 0.28 
23 
VRC-
PG04 light Y30 1.13 -0.16 0.23 -0.05 
26.13 
VRC-
PG04 light L91 0.97 -0.69 0.31 0.34 
20.4 
VRC-
PG04 light G31 0.47 -0.14 -0.03 0.04 
26.5 
VRC-
PG04 light F97 0.02 -0.02 0.74 0.17 
     RMSE 1.47 RMSE 1.27 RMSE 0.77 
*Use of the glycan-fragment containing model appears to require longer simulation times. The total 
RMSE for glycan-contacting cases is reduced from 1.47 kcal/mol without the glycan fragment to 0.77 
kcal/mol with the glycan fragment present and 100-ns runs. The reduction is RMSE is much more modest 
(1.47 to 1.27 kcal/mol) using the glycan fragment-containing model with the default 10-ns simulation length.  
4-2.5 Using Loop Prediction to Generate an Improved Initial Guess for Additive Mutations 
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Experience in using FEP for predicting small molecule binding affinities has shown that 
the initial guess for the structure can have a significant impact on the final results. The natural 
initial guess to use in the present case is the wild type homology model, and that is what we have 
done in the default protocol.  In most cases, this starting point yields reasonable results, suggesting 
that most mutations do not induce substantial conformational changes in the structure, and that 
such changes as are important are kinetically accessible in the course of the FEP simulation 
protocol. 
One situation where one might imagine that the initial guess would present difficulties is 
in the case of additive mutations (i.e. the final residue is larger in size than the initial one). The 
great majority of mutations studied in this paper do not fall into this category, for the simple reason 
that alanine is the second smallest of the amino acids.  When a larger residue is mutated to alanine, 
the structure is able to collapse around the space that is created, given sufficient time (doing so for 
Trp mutations understandably takes longer than for smaller residues). However, a Gly-to-Ala 
mutation could require substantial rearrangements of the structure.  
One way to address this problem is to use the endpoint structure corresponding to the larger 
of the two residues in the alchemical pair as the initial guess. A structure of the Ala mutant can be 
generated using the loop and side-chain prediction methods in the PLOP program [39, 40].  We 
have used this approach to generate predicted Ala structures for all of the cases where the wild-
type residue is a Gly, and then run FEP simulations in which the Ala structure is employed as the 
initial guess.  The results and comparison to the default protocol and experiment for individual 
cases can be found in the summary table (Table 4-5). For all cases but one, the errors are similar 
in magnitude (and consistent with the overall RMSE of the data set) for both starting points, 
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suggesting that for these cases, the barriers to interconversion in the FEP protocol are 
unproblematic. However, for the Gly 54 residue on the PG04 antibody, a significant difference is 
observed, with the Ala starting point yielding results that are much closer to experiment. 
Table 4-5: Summary of FEP cases showing the experimental value, default protocol 
value, modified protocol value (s) if any, final value in the revised protocol, and the 
change in absolute error from the default protocol in cases where the modified 
protocol applied. All values are in kcal/mol 




















VRC01  W100B 4.45 4.39 -- -- -- 4.59 -- 
VRC01  N58 1.76  -- -- -- 1.37 -- 
VRC01  Y100 1.42 -- -- -- -- 0.70 -- 
VRC01  V57 1.35 -- -- -- -- 1.18 -- 
VRC01  G54 -1.28 -- -- -- -- -0.37 -- 
VRC01  W50 1.28 -- -- -- -- 0.33 -- 
VRC01  G55 1.26 -- -- -- -- 0.78 -- 
VRC01  W47 1.19 -- -- -- -- 1.12 -- 
VRC01  N100A 1.11 -- -- -- -- 0.98 -- 
VRC01  V73 1.08 -- -- -- -- 0.46 -- 
VRC01  T33 0.70 -- -- -- -- 1.10 -- 
VRC01  Y59 0.54 -- -- -- -- -0.01 -- 
VRC01  M69 0.52 -- -- -- -- -0.37 -- 
VRC01  Q64 -0.35 -- -- -- -- 0.35 -- 
VRC01  Y74 -0.21 -- -- -- -- 0.48 -- 
VRC01  I30 -0.01 -- -- -- -- -0.35 -- 
VRC01  Y91 2.01 -- -- -- -- 0.50 -- 
VRC01  Y28 0.97 -- -- -- -- 0.20 -- 
VRC01  F97 0.85 -- -- -- -- 0.74 -- 
VRC01  Q27 -0.24 -- -- -- -- 0.16 -- 
VRC01  S30 -0.15 -- -- -- -- 0.03 -- 
VRC03  W47 1.48 -- -- -- -- 0.23 -- 
VRC03  W50 1.33 -- -- -- -- 2.68 -- 
VRC03  V57 1.25 -- -- -- -- 1.16 -- 
VRC03  S58 1.15 -- -- -- -- 0.90 -- 
VRC03  Q62 1.11 -- -- -- -- 2.36 -- 
VRC03  F100D 1.07 -- -- -- -- 1.19 -- 
VRC03  Y59 0.86 -- -- -- -- 0.49 -- 
VRC03  Y100 0.83 -- -- -- -- -0.03 -- 
VRC03  W54 0.76 -- -- -- -- 2.16 -- 
VRC03  G55 0.35 -- -- -- -- 1.20 -- 
VRC03  Q75 0.09 -- -- -- -- 0.25 -- 
VRC03  L53 0.05 -- -- -- -- 0.17 -- 
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VRC03  F91 -0.87 -- -- -- -- -0.02 -- 
VRC03  F97 0.83 -- -- -- -- 0.49 -- 
VRC03  Q27 -0.22 -- -- -- -- 0.26 -- 
VRC03  N30  0.195 -- -- -- -- 0.07 -- 
VRC-
PG04 
 N57 1.53 -- -- -- -- 1.04 -- 
VRC-
PG04 
 W50 1.28 -- -- -- -- -0.11 -- 
VRC-
PG04 
 W47 1.07 -- -- -- -- 0.86 -- 
VRC-
PG04 
 V56 0.99 -- -- -- -- 0.41 -- 
VRC-
PG04 
 T53 -0.85 -- -- -- -- 0.07 -- 
VRC-
PG04 
 V52B -0.82 -- -- -- -- 0.07 -- 
VRC-
PG04 
 G100A -0.63 -- -- -- -- -0.03 -- 
VRC-
PG04 
 L34 0.57 -- -- -- -- 0.06 -- 
VRC-
PG04 
 Y98 0.47 -- -- -- -- 0.46 -- 
VRC-
PG04 
 G54 0.46 -- -- -- -- -0.03 -- 
VRC-
PG04 
 T99 -0.43 -- -- -- -- -0.51 -- 
VRC-
PG04 
 G100 -0.27 -- -- -- -- 0.70 -- 
VRC-
PG04 
 G100C 0.19 -- -- -- -- 0.28 -- 
VRC-
PG04 
 G59 0.06 -- -- -- -- 0.51 -- 
VRC-
PG04 
 Y30 1.13 -- -- -- -- 0.02 -- 
VRC-
PG04 
 L91 0.97 -- -- -- -- 0.34 -- 
VRC-
PG04 
 V3 -0.51 -- -- -- -- -0.14 -- 
VRC-
PG04 
 G31 0.47 -- -- -- -- 0.04 -- 
VRC-
PG04 
 F97 0.02 -- -- -- -- 0.17 -- 
Analysis of the Gly and Ala endpoint structures for this case provides insight into the nature 
of the problem. The PG04 antibody heavy chain contains two neighboring arginines, residues R71 
and R73, whose interactions with gp120 can change under mutations on the CDR H2 loop.  In the 
wild type antibody, R71 forms an extremely stable salt bridge with an aspartic acid (D201 in our 
homology model, D368 in the 3SE9 crystal structure template used to build the RSC3 homology 
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model) on the gp120m, and R73 forms a stable contact with another residue on the antibody heavy 
chain.  This salt bridge was found to be persistent in all other FEP trials of VRCPG-04 mutations 
and also across multiple independent MD simulations, long MD simulations of the crystal structure 
and homology model complex, and in PLOP predictions of the wild CDR H2 loop with GLY at 
this position.  In contrast, in the Ala structure, the R71 side chain is predicted to shift away from 
the D201 side chain, with R73 moved into contact with D201. 
However, using the prediction for the mutant as the starting configuration for the 
FEP/REST run, we find that the mutant system stabilizes into a configuration where R73 replaces 
R71 in the contact with the gp120, approximately cancelling the effect of breaking the contact with 
R71 (see Figure 4-5).  The barrier to the R73 crossing into this configuration is sufficiently large 
that a 100ns trial is not sufficient to observe it, and it is doubtful it will be accessible to any tractable 
simulation length. The large number of atoms involved in the barrier likely also makes it 
inaccessible to inclusion in the REST region. These results suggest that in prospective predictions 
going forward that involve larger additive mutations, applying the PLOP protocol to predict the 
conformation of the mutant state will be a useful adjunct in achieving robust, accurate relative 
binding affinity prediction.  The net RMSE of the four CDR H2 loop cases is reduced from 1.78 
kcal/mol to 0.89 kcal/mol. The remaining glycine to alanine cases on the CDR H3 and CDR L1 
loops of VRCPG-04 mutations are identified as moderate or strong glycan contacts.  Loop 
predictions for these cases were performed with the glycan fragment present as well and included 
in the final protocol, and these are the values reported for these cases in Table 4-4.  The difference 





Figure 4-5: First and last frames of the wild (A to B) and mutant (C to D) phases for the VRC-PG04 
G54 mutation using the PLOP-predicted starting structure. The wild type phase regains the contact 
with the gp120 residue shown (B), which is found for the crystal structure based homology model 
and wild type loop prediction.  The mutant phase system maintains the contact between R73 and the 






4-2.6 Summary of suggested protocol improvements for FEP calculations of the effect of 
mutation at a protein-protein interface 
From the results discussed above, we can propose a protocol for running FEP calculations 
to predict the effects of protein mutations on protein-protein binding affinities. One study cannot 
completely define or validate a general protocol; it will require investigation of many more data 
sets to establish a prescription that can be viewed as fully reliable at a high level of accuracy. 
Nevertheless, we have identified a number of key problems specific to protein-protein FEP (as 
opposed to small molecule calculations), and developed solutions which perform well overall for 
the calculations run to date. We do expect that our protocol will prove useful in predicting 
antibody/gp120 interactions, based on the size of the data set that we have considered, and the 
quality of the results.  
The modifications we propose for protein-protein FEP calculations, as compared to 
protein-small molecule calculations, can be summarized as follows:  
(1) In small molecule FEP, the great majority of calculations are reasonably well converged 
with 10 nsec of simulation time. In contrast, a subset of the cases above required simulation times 
of 100 nsec.  This is clearly the case for tryptophan mutations, and for residues in contact with 
glycans.  These systems appear to require longer relaxation times, as is observed in trajectories of 
both the bound complex and (in at least one case) the antibody in solution. All such cases in the 
present data set have been run for 10-nsec, and the results are qualitatively superior to the 10-nsec 
runs. In future work, it may be the case that other types of mutations require longer running times; 
this is likely to be manifested in lack of convergence at the 10-nsec simulation mark. Much more 
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extensive exploration will be required to provide a complete, robust prescription as to when 
extended running times are required.  One could simply run all calculations for 100-nsec (or 
longer), however this necessitates the use of considerable additional GPU time. As GPU time 
becomes less expensive, it may make sense to adopt routine longer running times as a default 
protocol. At present, our specific recommendation is to run tryptophan mutations and glycan-
involved mutations out to 100 nsec, and to carefully examine default 10-nsec runs for other 
calculations for signs of poor convergence. 
 (2) We have shown that continuum solvent based loop and side-chain prediction can be 
helpful in improving convergence of the FEP simulations when mutating a smaller residue (in the 
present cases, this is always a Gly residue) to a larger residue (in the present paper, always an Ala).   
The specific, recommended protocol is to carry out loop/side chain prediction when the larger 
residue is the target residue and to use the predicted structure as the initial guess in the FEP 
simulations.  In prospective design applications aimed at increasing potency, there will be many 
changes other than Gly to Ala that fall into this category; indeed, many, if not most, favorable 
mutations are likely to be additive. Comparing more extensive results of this type with experiment 
will provide rigorous testing of this component of the recommended protocol in future work. 
4-2.7 Summary of results using recommended protocol 
Figure 4-6 presents the combined data for all three antibodies compared to experiment.  
Table 4-6 summarizes the RMSE and correlation results for all three bNAbs separately and for the 
full data set with and without glycan contacts. VRC03 contained the largest computed outliers as 
compared to the experiment in the set, which may have been the result of the particularly strong 
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chain of contacts between a glycan and the antibody light and heavy chain.  This may have had 
some effect on other residues on the heavy chain not in a direct sequence of contact.  The RMSE 
of the experimental results between re-measurements of the same system is estimated to be around 
0.45 kcal/mol for a typical case.  The overall uncertainty range in our predictions with this protocol 
are comparable to the experimental levels, as is confirmed by analysis of multiple independent 
FEP simulations, which gives an (full width) error estimate of about 0.51 kcal/mol. With the 
random error in the computed values and measurements both roughly 0.5 kcal/mol, the overall 
RMSE due to both theory and experiment would be expected to be around 0.7 kcal/mol, which is 
roughly what is found in the data presented here.  While individual cases likely still exhibit 
systematic errors associated with the sampling or protein force field, the magnitude of the overall 
RMSE for the three data sets, 0.70 kcal/mol, suggests that it will be increasingly difficult to 
distinguish experimental from computational error unless the experimental error can be reduced.   
      Table 4-6: Summary of results for the improved protocol.  RMSE values are in kcal/mol. 
 
without 
glycan contacts  
including 
glycan contacts  
data set RMSE correlation RMSE correlation 
VRC01  0.55 0.79 0.58 0.76 
VRC03 0.78 0.38 0.78 0.27 
VRCPG-04  0.56 0.48 0.68 0.22 
all three 




Figure 4-6: Experimental vs. FEP/REST relative binding affinity values for alanine scan cases 
showing the combined data set from VRC01 (circles), VRC03 (squares) and VRC-PG04 (triangles) 
4-2.8 Insights from FEP trajectories 
Analysis of trajectories generated from the FEP/REST alanine scan data can also be used 
to gain insights into the underlying reasons for the observed experimental and predicted changes 
in binding affinity.  Here, we focus on three notable cases: W100B and G54 on VRC01, and F100D 
on VRC03.  These cases are, respectively, the most unfavorable mutation experimentally, most 
favorable mutation experimentally, and an example of a case where the glycan affects a mutation 
indirectly through its direct interaction with another antibody residue, F91 on the light chain.  
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The first case, W100B, was the most unfavorable mutation in the alanine scan cases. Its 
indole nitrogen forms a highly stable hydrogen bond with a gp120 sidechain (GLU 204 the RSC3 
homology model) and also formed very stable pi-stacking interactions with two adjacent residues 
(Y100 and W47) that appear important in stabilizing the overall binding mode of VRC01 with 
gp120 (see the top panel of Figure 4-7).  The latter effectively anchor the long flexible CDR H3 
loop to the sheet that W47 is on.  In the bottom panel of Figure 4-7, several frames from the wild 
and mutant replicas are shown together, aligned to the backbone of the first wild frame. With 
W100B present, W100B (and Y100, not shown) is aligned well with the light chain, constraining 
the CDR H3 loop configuration.  In the mutant end trajectory frames, in contrast, the much smaller 
alanine is essentially uncorrelated with the alignment of the light chain backbone, and the CDR 
H3 loop is able to assume a more favorable backbone configuration, explaining at least part of the 
slow relaxation.  The mutant trajectory frames also show a noticeable shift in overall alignment 
between the heavy and light chains and the bNAb and the gp120.  In addition to explaining the 
high unfavorability of the W100B to ALA mutation, this also explains why W47, which appears 
to have no direct contacts with the gp120, gives an unfavorable result upon mutation to ALA. The 
very stable contact with W100B also likely explains why Y100 on VRC01 shows little sensitivity 
to the presence of the glycan fragment NAG776, despite being in direct contact with it, as it cannot 
shift into the space of the missing glycan when no fragment was included,  due to the interaction 
with W100B.  From the standpoint of future binding affinity optimization efforts, W100B and the 
residues contacting it are likely poor candidates for modification, as there is a large cost to 





Figure 4-7: top: Loss of the hydrogen bond of W100B (center) with gp120 residue A141 
(dashed yellow line) as well as stabilizing network of pi-pi stacking interactions (dashed 
light blue lines) results in the large unfavorable effect upon mutation to alanine.  Bottom:  
5 frames from the end of the wild end (green) and 5 frames from the end of the mutant end 
trajectory (blue) with light chain backbones aligned to the first wild frame are shown with 




 G54 on the heavy chain of VRC01 is the most favorable mutation experimentally, and it 
can be seen from the trajectories that this is likely because the inserted alanine forms a favorable 
hydrophobic interaction with an isoleucine (I204 in the RSC3 homology model) on the gp120, 
whereas the glycine leaves a gap large enough for water to occupy (see Figure 4-8). In the FEP 
simulations starting from the model structure (with the re-predicted mutant CDR H2 loop, as per 
the protocol outlined above), there are initially no waters present in the region between G54 and 
I204. The degree of water penetration differed with initial velocity seeds, resulting in variance 
somewhat higher than average in the FEP results, suggesting that future refinements to the protocol 
better place solvent initially may help attain better convergence in certain cases.   
 
The observed geometry in the trajectory frames also suggests the possibility that some 
further optimization of this hydrophobic contact might be possible by substituting valine or leucine 
in for G54 instead of alanine. FEP/REST applied to mutations to valine predicts ∆∆G of -1.90, as 
its greater size is better able to fill the space between the CDR H2 loop and I204 on the gp120.  It 
does not appear that further mutations to larger hydrophobic side chains will be able to further 
improve this, as mutation to leucine already requires a re-orientation of side chains to avoid a clash.  
FEP/REST predicts that leucine performs comparably by assuming a different orientation from 
alanine and valine (∆∆G = -1.79), but it is likely larger residues will degrade this by destabilizing 
the nearby salt bridge between R71 on the bNAb heavy chain and D201 on the gp120 model.  Thus 






Figure 4-8: The mutation of G54 (top) to A54 on the heavy chain results in an improved 
hydrophobic contact with I204 on the gp120, resulting in the favorable change in binding 
affinity observed for this mutation. 
87 
 
Finally, we consider an illustrative case that is sensitive to the presence of the glycan 
fragment, and shows how sequences of aromatic side chains can propagate interactions with the 
glycan fragments not in direct contact with the residue to be mutated.  F100D on the heavy chain 
of VRC03 forms a strong hydrophobic contact with the nearby residue F91 on the light chain; 
however, the presence of NAG776 in the model disrupted this contact, pushing away the F91 
sidechain far enough away to allow water penetration between the two phenyl side-chains (see 
Figure 4-9).  As a result of this, FEP without the glycan fragment NAG776 predicted these 
mutations as substantially more unfavorable than they are.  Although the lack of the full glycan 
structure may slightly underestimate the unfavorability of the F91-glycan interaction, the results 
of FEP on the system including NAG776 are able to bring both to within 1 kcal/mol of the 





Figure 4-9: The hydrophobic contact between F100D and F91 does not form with the glycan 
fragment NAG776 included, leading to the significantly less unfavorable results consistent with 
experiment 
4-2.9 Comparison with empirical method 
For comparison, we show the results of FEP/REST in comparison to foldX [31], a popular 
empirical method of predicting alanine scan mutation values, which takes a negligible amount of 
computing time compared to the FEP/REST simulation time (less than 5 minutes per structure on 
a single processor vs ~12-72 hours on 4 gpu cards for FEP/REST simulations). As foldX has no 
ability to treat the glycan fragment, we limit the comparison here to the 38 cases identified as 
insignificantly glycan-contacting. The results of FEP/REST over the full set show a substantially 
lower RMSE (0.64 vs 1.02 kcal/mol) and a substantially better correlation (fit line r2 of 0.62 vs 
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0.15) than the results of foldX on the same set.  The foldX RMSE of 1.02 kcal/mol only slightly 
lower than the null hypothesis result of 1.14 kcal/mol obtained by taking all calculated results to 
be 0.  This favorable comparison holds up even with the removal of the largest experimental ∆∆G 
value point from the set (RMSE 0.64 vs 1.00 for foldX; r2=0.39 vs r2=0.05 for foldX).  Figure 4-
10 shows the combined data from the 44 cases using FEP/REST together with the results from 
foldX for comparison. The foldX correlation coefficient is sufficiently small as to render the results 
of little utility in making actionable predictions in prioritizing mutations. The RMS error of foldX 
is respectable primarily because most of the predictions are close to zero free energy change, as 
are many of the experiments.  
 
Figure 4-10: Combined set of mutations for VRC01, VRC03 and VRC-PG04 (filled circles) with 





The experimental data presented in this study reveals that a subset of contact residues have 
greater impact on binding affinity, suggesting these contacts account for the high binding affinity 
observed between VRC01-like antibodies and HIV-1 gp120. There are common locations across 
all three antibodies which result in ∆∆G values in excess of 1kal/mol when mutated to alanine, 
such as W47, W50 and R71. Another interesting result lies in the N-terminal of all three antibodies’ 
light chains. Alanine mutation of N terminal contacting residues resulted in ∆∆G lower than -
0.5kcal/mol, suggesting optimization in the area could improve antibody potency. Even though 
there are a number of commonalities among the three antibodies, their energy landscapes differ in 
a number of ways. VRC01 G54 mutant had a ∆∆G of -1.2kcal/mol, however in VRC03, similar 
contact G55 mutant had a ∆∆G of 0.8kcal/mol. In another example, in VRC-PG04 G100A had 
∆∆G of -0.6kcal/mol in contrast to VRC01 N100A mutants with a ∆∆G of 1.1kcal/mol.  
The results here demonstrate that FEP/REST can be successfully applied across a large 
number of mutations in a protein-protein complex to give meaningful predictions of relative 
binding affinity.  To our knowledge this is the first such large scale application of FEP to any 
protein-protein complex, let alone one of with the significant complications encountered here.  The 
difficulties associated with homology modeling, glycosylation effects, relaxation times, and loop-
level sampling of additive mutations appear to be effectively addressable with the current version 
of the FEP/REST software and the computational resources available.  The level of accuracy 
presented here appears to be sufficient for screening prospective mutations for effectiveness in 
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increasing binding affinity with a useful rate of success, although this will need to be validated by 
actual prospective calculation.  
The current data set has provided a broad exploration of the issues that complicate the 
application of FEP/REST to protein complexes.  While we have been able to demonstrate that long 
simulation times are required for some residue types and that even small additive mutations can 
result in large structural re-arrangements necessitating the use of loop and side-chain prediction, 
more test sets are needed to generalize and refine these protocols.   
There remain some outstanding sampling issues for a small handful of cases in the set.  In 
particular, in one case on the H2 loop of VRC-PG04, T53 shows much more sensitivity to small 
changes in initial conditions than most of the other cases.  This case is adjacent to the G54 case 
discussed in detail previously, and may be of similar origin. An additional issue is that the case 
cited above is experimentally determined to result in more favorable binding affinity, despite the 
reduction in size of the residue from threonine or valine to alanine.  In general, one would expect 
that most such cases must arise because of favorable, relatively complex re-arrangements in the 
surrounding residues at the interface, and capturing such rearrangements is a larger sampling 
problem than capturing effects more localized around the target residue.  From our current results, 
longer simulation times on the order of 100 nsec appear unable to resolve these cases. More 
extensive conformational sampling might be able to address such cases with a higher degree of 
effectiveness.  It is also possible, however, that experimental noise is a significant contributor to 
the disagreement between theory and experiment. Hence, a more intensive investigation of all 
aspects of these cases is called for in future works. 
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As noted previously, mutations in which the net charge of the system is changed present 
significantly greater difficulties for FEP simulations due to periodic boundary condition artifacts, 
as has been investigated by Parameswaran et al. and Rocklin et al. [27,28], Lin and coworkers [41], 
and Reif and Oostenbrink [42]. These authors have suggested a posteriori corrections using 
Poisson Boltzmann (PB) electrostatics to ameliorate these problems, a technique which appear to 
be promising. However, there are other issues when the net charge of the system is changed by a 
mutation which are not addressed by PB corrections, for example, the possibility of large structural 
rearrangements,  and the potential for changes in pKa between wild-type and mutant systems. We 
are in the midst investigating the methodologies for correcting for boundary condition artifacts 
using PB corrections in conjunction with other strategies such as running the simulations with the 
experimental concentration of explicit ions and simultaneous creation/annihilation of counter-ions 
to keep the system neutral during the course of FEP simulations. The problems due to large scale 
rearrangements, and changes of protonation state upon mutation, pose fundamental issues in 
improving the sampling of the simulations to address major changes in loop conformations, and 
the use of techniques such as constant pH simulation to handle protonation state changes. Finally, 
the accuracy of the potential energy function in cases where there is a change in charge needs to 
be calibrated; this however can only be attempted when the key sampling issues have been 
addressed.  A solution to these challenges is essential if FEP is to be used effectively in facilitating 
antibody design and optimization, as the change of a charged residue to a neutral or oppositely 
charged residue (or change of a neutral residue to a charged residue) will often be a useful 
modification. 
4-4 Models and methods 
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4-4.1 Experimental alanine scans 
We mutated each contact of VRC01, VRC03, and VRC-PG04 to alanine, expressed the 
altered Fab antibody fragment, measured their affinities for HIV-1 gp120 using an Octet biosensor, 
and calculated changes of Gibbs free energy (∆G). Alteration of VRC01 glycine 54 to alanine in 
some cases enhanced affinities, suggesting that a hydrophobic residue at this position might lead 
to enhanced antibody potency. Characterizations of the interacting energy landscape between 
VRC01-like antibodies and HIV-1 gp120 thus provide a rational basis for germline origin and 
suggest ways to enhance potency. 
VRC01, VRC03 and VRC-PG04 alanine mutants were generated by substituting individual 
antibody amino acids at the Ab-gp120 interface to alanine. Only contacting amino acids with 
buried surface area greater than 5 Å2 were chosen for the alteration (contacting residues defined 
in Zhou 2010 VRC01 structure paper [11]). HIV-1 gp120 core protein RSC3 was used for all 
binding experiments [10]. RSC3 protein and antibodies were produced in 293 FreeStyle cells and 
purified with a protein A immobilized 17b antibody affinity column and a protein A column 
respectively.  
A fortéBio Octet Red384 instrument was used to measure binding kinetics of wild type and 
alanine mutant antibodies to gp120. All assays were performed with agitation set to 1,000 rpm in 
Kinetics Buffer (ForteBio). The final volume for all solution was 50 μl/well. Assays were 
performed at 30°C in tilted black 384-well plates (Geiger Bio-One). Anti-Human Fc sensor tips 
(ForteBio) were used to capture Fabs for 300s. Biosensor tips were then equilibrated for 90 s in 
Kinetics Buffer prior to measuring association with RSC3 proteins in solution for 300 s; sensor 
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tips were then allowed to dissociate for 300 s. Parallel correction to subtract systematic baseline 
drift was carried out by subtracting the measurements recorded for a loaded sensor incubated in 
Kinetics Buffer. Data analysis and curve fitting were carried out using Octet software, version 8.0. 
Experimental data were fitted with the binding equations describing a 1:1 interaction. Global and 
local analyses of the data sets assuming reversible binding (full dissociation) were carried out using 
nonlinear least-squares fitting allowing a single set of binding parameters to be obtained 
simultaneously for all of the concentrations used in each experiment. 
Binding free energy for each alanine mutant was calculated using the formula ∆G = 
RTln(KD), where R is the ideal gas constant, T is the absolute temperature, and KD is the 
dissociation constant (Koff/Kon). The change in the binding free energy between the alanine mutant 
and respective wild type antibody (∆∆G) was calculated by subtracting ∆Gwt from ∆Gmutant with 
positive ∆∆G signifying decrease in affinity of the antibody to gp120 as a result of alanine 
substitution. Values for all mutations performed as part of this set are reported in Table 4-1.  
4-4.2 Homology model building methods for gp120/RSC3 Complexes  
For each of the three wild type complexes, a model for the complex with the RSC3 gp120 
was built using an available crystal structure (PDB structure 3NGB for VRC01, PDB structure 
3SE8 for VRC03, and PDB structure 3SE9 for VRC-PG04 The sequence alignment between RSC3 
and the gp120 strain in the template crystal structure were optimized using ClustalW [43], yielding 
a sequence identity of 50%, a sequence similarity of 63%, and gaps of 11%. The models were built 
using a knowledge-based approach (described in more detail in ref. [44], where it was applied to 
the prediction of loops in homology models of antibodies), whereby insertions and deletions in the 
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sequence alignment, as well as any missing backbone coordinates from the template itself, were 
reconstructed using a library of loop fragments of similar length from other known PDB structures. 
These candidate loop fragments were then filtered according to their stem geometry to discard 
those which cannot form reasonable connections with the existing model, and the surviving 
fragments were then positioned in the model by superposition of the attachment residues.  Loops 
which clash with the protein, or with each other, were discarded, and the surviving loops were then 
ranked by sequence similarity using BLOSSUM62 [45], with the highest sequence similarity loop 
being chosen.  
The side chain conformations of residues which were conserved in the sequence alignment 
were retained, while the conformations of all other side chains (including all residues involved in 
the loop building described above) were iteratively sampled using a coarse library of rotamers 
derived from known PDB structures until no clashes remained [44].  The coordinates of all atoms 
not derived directly from the template itself were then minimized, producing the final model. The 
antibodies were not present in the RSC3 model building process, however differences in the 
binding interface between the template structure taken from complexes with the three different 
antibodies are retained in the three different RSC3 models   
The antibody from the crystal structure was then aligned with this homology model. First 
the homology model of the gp120 protein was aligned with the gp120 protein from the crystal 
structure bound to the antibody in such a way that the crystal structure antibody is moved by the 
same displacement and rotation. The antibody from the crystal structure was then merged with the 
homology model of the RSC3 gp120 sequence, using the relative orientation generated by aligning 
the gp120 proteins.  Several rounds of sidechain optimization on the RSC3 gp120 protein in 
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complex with the antibody were then performed using the Prime program [46,47].  The regions of 
the antibody chains that are distant from the binding region were truncated to reduce the system 
size, and the resulting structure was prepared for molecular dynamics (MD) simulations by adding 
hydrogens corresponding to physiological pH.  The resulting set encompasses mutations of 20 
residues from VRC01, 11 from VRC03, and 15 from VRC-PG04, from their wild type identity to 
alanine, across the three antibodies considered.   
The net difference between the common parts of the gp120 protein in the crystal structure 
from the gp120 homology model is quite small; the heavy atom RMSDs for the common parts of 
the template and RSC3 sequence are 0.66 Angstroms for VRC01 (0.38 Angstroms for only 
backbone atoms), 0.37 Angstroms for VRC03 (0.38 Angstroms for only backbone atoms) and 0.45 
Angstroms for VRC-PG04 (0.40 Angstroms for backbone atoms).  No residues whose backbones 
had to be predicted because of insertions or deletions from the template structure are within 5 
Angstroms of any residue on the antibody and only a single residue backbone insertion point is 
within 10 Angstroms of the antibody.  The backbone structure in the interface region is nearly 
identical to the template, save for one loop in the template that does not occur in the RSC3 model. 




Figure 4-11: Comparison of crystal structure from PDB ID 3NGB (red) to the RSC3 homology 
model structure (blue). The antibody is shown in black for reference.  
Each antibody-homology model complex was further validated with a 100ns MD 
simulation to verify that the binding properties with the antibody using the homology model were 
stable under thermal conditions.  Comparing simulations using the template crystal structures 
shows that the identified binding regions show comparable stabilization in both crystal structures 
and homology models, with backbone rmsds in both stabilizing below 2.0 Angstroms from the 
input structures.  We conclude from this that the homology model provides a reasonable 





Given the close homology in the CD4 binding region between the gp120 variant used in 
the experiments and in the crystal structures of 3NGB, 3SE8 and 3SE9, it is a plausible hypothesis 
that the glycans in the experimental system occupy similar positions in the experimental 
gp120/antibody complex as in the crystal structures.  As noted previously, only one of the glycan 
fragments, NAG776, is close enough to any of the sites of mutation to induce a large direct effect 
on the change in binding free energy upon mutation.   
Figure 4-12 shows the glycan fragment NAG776 in the 3NGB structure which is in clear 
contact with the antibody binding region.  Based on the hypothesis that the effects of NAG776 can 
be largely captured by including the part that has been observed in the crystal structures, we 
performed FEP/REST on the 17 cases identified as potential direct or indirect glycan contacts from 
the crystal structure. Short MD simulations were performed to determine likely glycan contacts.  
Direct contacts score was defined by a simple inter-atomic contact counts, scaled with a sigmoidal 
cutoff around 4Å, and averaged over simulation frames.  Indirect contacts were defined by scoring 
contacts of aromatic side chain residues (tryptophan, tyrosine, and phenylalanine) with direct 
contacts and with aromatic side chain contacts of direct contacts, with a higher contact score 
threshold. Details of the scoring parameters used are provided in the SI.  While in some cases, the 
fragment included may not capture the full set of interactions with the glycan, especially for 
residues on the light chain away from the heavy light chain interface, for many cases the inclusion 





Figure 4-12: The glycan fragment on gp120 residue N276 captured in the 3NGB crystal structure, 
N776, is shown with the 3 cases identified as suspected glycan contacts (Y104, Y91, and Y104) 
4-4.3 FEP Molecular Dynamics Simulations 
Default Small Molecular Protocol (10 nsec runs) 
 
All simulations were performed using the Desmond molecular dynamics program [48–50].  Input 
structures are solvated with a 5Å buffer of spc water in a rectangular box.  For each case a short 
relaxation phase, with a combination of minimization and restrained molecular dynamics phases, 
was performed to equilibrate the system.  Each equilibrated structure was then input into a 10ns 
100 
 
FEP/REST simulation to calculate the change in Gibbs free energy, ∆G, with the difference 
between the bound and unbound simulations giving the relative binding affinity (∆∆G).  This 
protocol uses 12 lambda-windows in the FEP/REST schedule run for 10ns with the side chain of 
the residue being mutated included in the REST hot region.  The FEP/REST phase was performed 
in the NPT ensemble with a Berendsen thermostat and barostat.  The equations of motion were 
integrated using a RESPA scheme with an inner time step of 2.0fs and an outer time step of 6.0fs. 
Modified Simulation Protocols 
For TRP cases, and cases where the glycan fragment is included in the model gp120-bNAb 
complex, simulations time for the FEP/REST phase of the simulation are extended from 10ns to 
100ns.  For glycine to alanine mutations, the antibody loop containing the glycine residue is re-
predicted, along with surrounding sidechain conformations, with the alanine replacing the glycine.  
This structure with the re-predicted loop on the antibody is then used as the input for the full 
simulation protocol, with the same equilibration cycle and 10ns (100ns for glycan contacts) 
FEP/REST simulation cycle.  For glycan contacts, the loop prediction is performed with the glycan 
fragment present in the structure.  All cases with the glycan fragment present use 100ns FEP/REST 
phases.  In addition, for any remaining 10ns simulations which show greater than 0.5 kcal/mol 
differences between the 2 independent trials of one simulation leg, 3 additional independent trials 
seeded with different randomly generated initial velocities are performed and included in the 




4-5 Conclusions  
We have shown here a proof of concept that FEP/REST can be used to predict the relative 
binding affinities of a large set of alanine scan data.  Several protocol refinements and modeling 
improvements have been put forward which reduce the overall error in the data set to a level that 
is comparable to the estimated experimental uncertainty. As noted above, the present protocol is 
incomplete in that we have not yet demonstrated the ability to treat mutations in which the net 
charge on the protein is changed.  The use of Poisson-Boltzmann calculations, to correct for 
periodic boundary condition effects, combined with the inclusion of appropriate ionic strength, is 
a promising approach to this problem, and can readily be tested using the data sets discussed here. 
Work along these lines is currently in progress.  
While there is reason to be optimistic that the protocols described here could be profitably 
applied to predict the effects of mutation for a wide range of protein-protein interactions, new 
problems may arise for different systems.   Hence, application of the present methodology across 
a diverse set of protein-protein complexes is essential for assessment of broad applicability.  We 
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